{"content":"<li class=\"n-box-item date-title\" data-end=\"1540007999\" data-start=\"1539921600\" data-txt=\"Monday, December 23, 2019\">Friday, October 19, 2018</li><li class=\"n-box-item sa-box-item\" data-id=\"3399058\" data-ts=\"1539985829\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GARS\" target=\"_blank\">GARS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399058-after-hours-gainers-losers-10-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">After Hours Gainers / Losers (10/19/2018)</a></h4><ul><li><b>Top Gainers:</b> <a href='https://seekingalpha.com/symbol/GARS' title='Garrison Capital'>GARS</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/PVTL' title='Pivotal Software'>PVTL</a> <font color='green'>+4.7%</font>. <a href='https://seekingalpha.com/symbol/NKTR' title='Nektar Therapeutics'>NKTR</a> <font color='green'>+3.8%</font>. <a href='https://seekingalpha.com/symbol/CCJ' title='Cameco Corporation'>CCJ</a> <font color='green'>+3.2%</font>. <a href='https://seekingalpha.com/symbol/GDS' title='GDS Holdings'>GDS</a> <font color='green'>+2.8%</font>.</li><li><b>Top Losers:</b> <a href='https://seekingalpha.com/symbol/BHF' title='Brighthouse Financial, Inc.'>BHF</a> <font color='red'>-4.4%</font>. <a href='https://seekingalpha.com/symbol/ALT' title='Altimmune, Inc.'>ALT</a> <font color='red'>-2.2%</font>. <a href='https://seekingalpha.com/symbol/TSRO' title='Tesaro'>TSRO</a> <font color='red'>-1.6%</font>. <a href='https://seekingalpha.com/symbol/OMER' title='Omeros Corporation'>OMER</a> <font color='red'>-1.5%</font>. <a href='https://seekingalpha.com/symbol/BMY' title='Bristol-Myers Squibb Company'>BMY</a> <font color='red'>-1.5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399058\" data-linked=\"After Hours Gainers / Losers (10/19/2018)\" data-tweet=\"$GARS $GARS $PVTL - After Hours Gainers / Losers (10/19/2018) https://seekingalpha.com/news/3399058-after-hours-gainers-losers-10-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3399058-after-hours-gainers-losers-10-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  5:50 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399035\" data-ts=\"1539979409\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XM\" target=\"_blank\">XM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399035-surveymonkey-drops-competitor-files-for-200m-ipo\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SurveyMonkey drops as competitor files for $200M IPO</a></h4><ul><li>        Survey software Qualtrics (QTIC) <a href=\"https://www.sec.gov/Archives/edgar/data/1747748/000162828018012674/qualtricss-1.htm\" target=\"_blank\">files</a> for a $200M IPO. The company wants to list on the Nasdaq under the ticker &ldquo;XM,\" which is also the name of its platform.&nbsp;&nbsp;</li><li>        In the first six months of this year, Qaultrics had a loss of $3.4M on $184.2M in revenue. In last year&rsquo;s period, there was a $3.7M loss on $121.4M in revenue.</li><li>               The company has raised around $450M in VC money from the likes of Accel, Insight Venture Partners, and Sequoia Capital.&nbsp;</li><li>                  Competitor: SurveyMonkey (NASDAQ:<a href='https://seekingalpha.com/symbol/SVMK' title='SurveyMonkey'>SVMK</a>), which went public at the end of last month. SVMK closed today&nbsp;<font color='red'>down 5.3%</font>.&nbsp;   &nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3399035\" data-linked=\"SurveyMonkey drops as competitor files for $200M IPO\" data-tweet=\"$XM $XM $SVMK - SurveyMonkey drops as competitor files for $200M IPO https://seekingalpha.com/news/3399035-surveymonkey-drops-competitor-files-for-200m-ipo?source=tweet\" data-url=\"https://seekingalpha.com/news/3399035-surveymonkey-drops-competitor-files-for-200m-ipo\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  4:03 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399029\" data-ts=\"1539979115\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VFC\" target=\"_blank\">VFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399029-vf-corpminus-10-on-worries-over-jeans-business\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VF Corp. -10% on worries over jeans business</a></h4><ul>     <li>VF&nbsp;Corp. (<a href='https://seekingalpha.com/symbol/VFC' title='V.F. Corporation'>VFC</a> <font color='red'>-10.7%</font>) plunges to its lowest level in five months despite <a href=\"https://seekingalpha.com/news/3398863-vf-corp-moves-q2-beat-upsized-guidance-dividend-hike\" target=\"_blank\">beating Q2 expectations</a> for earnings and revenues while raising FY 2019 guidance and hiking its dividend, as investors focused on <a href=\"https://www.reuters.com/article/us-vf-results/lee-wrangler-owners-shares-fall-9-percent-on-fading-jeans-business-idUSKCN1MT24N\" target=\"_blank\">declining revenue in VF's jeans segment</a>.</li>     <li>VF had anticipated flat growth in the category for 2019 but it now forecasts a 1%-2% revenue decline; for Q2, Wrangler revenues fell 5% Y/Y and Lee slumped 9%.</li>     <li>&ldquo;While the results were generally strong, the lack of upside on gross margin and the deterioration in the jeans business, led by Lee... raise some questions around the story,&rdquo; says Wedbush analyst Christopher Svezia.</li>     <li>In August, VF said it would spin off its less profitable Wrangler and Lee jeans into a publicly traded company, allowing it to focus on Vans and its outdoor wear businesses to help improve profit margins.</li>     <li>VF also says it is \"closely monitoring\" the China-U.S. trade situation, as ~11% of the company's total cost of goods sold come directly to the U.S. from China.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399029\" data-linked=\"VF Corp. -10% on worries over jeans business\" data-tweet=\"$VFC - VF Corp. -10% on worries over jeans business https://seekingalpha.com/news/3399029-vf-corpminus-10-on-worries-over-jeans-business?source=tweet\" data-url=\"https://seekingalpha.com/news/3399029-vf-corpminus-10-on-worries-over-jeans-business\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:58 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>24&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399028\" data-ts=\"1539977831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RDC\" target=\"_blank\">RDC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399028-rowan-wins-new-work-for-idle-jack-up-rig\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Rowan wins new work for idle jack-up rig</a></h4><ul>     <li>Rowan (<a href='https://seekingalpha.com/symbol/RDC' title='Rowan Companies plc'>RDC</a> <font color='green'>+1.4%</font>) is rising after its <a href=\"http://s2.q4cdn.com/240362030/files/doc_downloads/2018/10/Fleet_Status_Report_101818_Final_Draft.pdf\" target=\"_blank\">latest fleet status report</a> reveals Freeport McMoRan <a href=\"https://www.offshoreenergytoday.com/rowan-lands-new-gig-for-idle-jack-up-rig/\" target=\"_blank\">hired one of its idle jack-up drilling rigs</a> for work in the Gulf of Mexico.</li>     <li>FCX will be using the <em>Rowan EXL III</em> for one well beginning late this month at an undisclosed  dayrate; the rig has been idle since the middle of August.</li><li>RRC also says U.S. oil company LLOG has&nbsp;exercised the first of its two one\u2010well priced options for the <em>Rowan Resolute</em> drillship, whose three\u2010well contract with LLOG started in mid\u2010June 2018.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399028\" data-linked=\"Rowan wins new work for idle jack-up rig\" data-tweet=\"$RDC - Rowan wins new work for idle jack-up rig https://seekingalpha.com/news/3399028-rowan-wins-new-work-for-idle-jack-up-rig?source=tweet\" data-url=\"https://seekingalpha.com/news/3399028-rowan-wins-new-work-for-idle-jack-up-rig\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  3:37 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399016\" data-ts=\"1539975168\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TSLA\" target=\"_blank\">TSLA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399016-electrek-tesla-maintaining-near-1000-vehicle-day-production-pace\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Electrek: Tesla maintaining near 1,000-vehicle/day production pace</a></h4><ul>   <li>Tesla (<a href=\"http://seekingalpha.com/symbol/TSLA\" target=\"_blank\">TSLA</a> <font color='red'>-2.8%</font>) is currently maintaining production of <a href=\"https://electrek.co/2018/10/19/tesla-maintain-production-1000-vehicles-day/\" target=\"_blank\">close to 1,000 vehicles per day</a>, Electrek says, with most of those Model 3 vehicles.</li>    <li>The publication cites a source saying the automaker made about 6,800 cars over the past week, including about 4,800 Model 3s.</li>    <li>That would make about 18,300 vehicles for the quarter so far, with 12,200 of those Model 3s.</li>    <li>For its part, Tesla is saying it's \"achieved a steady volume in manufacturing capacity.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398869-teslas-china-plan-needs-time-money-heard-street\" target=\"_blank\">Tesla's China plan needs more time/money - Heard on the Street</a> (Oct. 19 2018)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399016\" data-linked=\"Electrek: Tesla maintaining near 1,000-vehicle/day production pace\" data-tweet=\"$TSLA - Electrek: Tesla maintaining near 1,000-vehicle/day production pace https://seekingalpha.com/news/3399016-electrek-tesla-maintaining-near-1000-vehicle-day-production-pace?source=tweet\" data-url=\"https://seekingalpha.com/news/3399016-electrek-tesla-maintaining-near-1000-vehicle-day-production-pace\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>419&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399015\" data-ts=\"1539975151\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCTY\" target=\"_blank\">NCTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399015-technology-top-5-gainers-losers-of-2_50-pm-10-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Technology - Top 5 Gainers / Losers as of 2.50 PM (10/19/2018)</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+111%</font>. <a href='https://seekingalpha.com/symbol/ABIL' title='Ability Inc.'>ABIL</a> <font color='green'>+31%</font>. <a href='https://seekingalpha.com/symbol/ELTK' title='Eltek Ltd.'>ELTK</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/MTSL' title='MER Telemanagement Solutions Ltd.'>MTSL</a> <font color='green'>+13%</font>. <a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a> <font color='green'>+14%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SREV' title='ServiceSource International, Inc.'>SREV</a> <font color='red'>-46%</font>. <a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a> <font color='red'>-19%</font>. <a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a> <font color='red'>-17%</font>. <a href='https://seekingalpha.com/symbol/LLNW' title='Limelight Networks, Inc.'>LLNW</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/YNDX' title='Yandex N.V.'>YNDX</a> <font color='red'>-12%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3399015\" data-linked=\"Technology - Top 5 Gainers / Losers as of 2.50 PM (10/19/2018)\" data-tweet=\"$NCTY $NCTY $ABIL - Technology - Top 5 Gainers / Losers as of 2.50 PM (10/19/2018) https://seekingalpha.com/news/3399015-technology-top-5-gainers-losers-of-2_50-pm-10-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3399015-technology-top-5-gainers-losers-of-2_50-pm-10-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:52 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399011\" data-ts=\"1539974374\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ERJ\" target=\"_blank\">ERJ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399011-embraerminus-2-backlog-hits-five-year-low\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Embraer -2% as backlog hits five-year low</a></h4><ul>     <li>Embraer (<a href='https://seekingalpha.com/symbol/ERJ' title='Embraer S.A.'>ERJ</a> <font color='red'>-2.5%</font>) reports the <a href=\"https://www.reuters.com/article/embraer-backlog/update-1-embraers-backlog-hits-five-year-low-as-sales-slump-idUSL2N1WZ0EB\" target=\"_blank\">backlog for its planes fell to $13.6B</a> at the end of Q3 from $17.4B at the close of Q2 and $18.8B, hitting its lowest level in more than five years.</li>     <li>ERJ says deliveries of commercial planes also fell sharply to 15 commercial aircraft vs. 25 at the end of Q3 2017, although deliveries of private jets rose to 24 aircraft from 20 a year ago.</li>     <li>ERJ says the backlog fell mostly due to the removal of two orders: JetBlue canceled an order of 24 planes after announcing in July that it would use Airbus jets to replace its aging Embraer fleet, and a 100-plane order from Skywest was dropped due to uncertainty about whether pilots would agree to fly its E175-E2 for U.S. regional carriers.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399011\" data-linked=\"Embraer -2% as backlog hits five-year low\" data-tweet=\"$ERJ - Embraer -2% as backlog hits five-year low https://seekingalpha.com/news/3399011-embraerminus-2-backlog-hits-five-year-low?source=tweet\" data-url=\"https://seekingalpha.com/news/3399011-embraerminus-2-backlog-hits-five-year-low\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399005\" data-ts=\"1539972284\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IBM\" target=\"_blank\">IBM</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399005-stat-ibm-watson-health-head-steps-down\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">STAT: IBM Watson Health head steps down</a></h4><ul><li>        STAT <a href=\"https://www.statnews.com/2018/10/19/head-of-ibm-watson-health-leaving-post/?utm_content#61;buffer64e12&amp;utm_medium&amp;\" target=\"_blank\">reports</a> that IBM (<a href='https://seekingalpha.com/symbol/IBM' title='International Business Machines Corporation'>IBM</a> <font color='red'>-1.3%</font>) Watson Health head Deborah DiSanzo is leaving her role for a position on the company&rsquo;s Cognitive Solutions strategy team.&nbsp;</li><li>               John Kelly, current SVP for Cognitive Solutions and IBM Research, will step into the vacancy.&nbsp;</li><li>               Watson Health has hit some bumps with its flagship cancer software earning criticism from some internal and external doctors and the business struggling to integrate acquisitions.</li><li>               During this week&rsquo;s earnings report, the Cognitive Solutions segment reported revenue that was down 5% Y/Y.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397849-ibm-q3-revenue-miss-server-weakness-cognitive-solutions-drop\" target=\"_blank\">IBM Q3: Revenue miss, server weakness, and Cognitive Solutions drop</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3399005\" data-linked=\"STAT: IBM Watson Health head steps down\" data-tweet=\"$IBM - STAT: IBM Watson Health head steps down https://seekingalpha.com/news/3399005-stat-ibm-watson-health-head-steps-down?source=tweet\" data-url=\"https://seekingalpha.com/news/3399005-stat-ibm-watson-health-head-steps-down\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:04 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>53&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399002\" data-ts=\"1539972041\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PKD-OLD\" target=\"_blank\">PKD-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399002-energy-materials-top-5-gainers-losers-of-2-00-pm-10-19-2018\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Energy/Materials  - Top 5 Gainers / Losers as of 2:00 PM (10/19/2018)</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/PKD-OLD' title='Parker Drilling Company'>PKD-OLD</a> <font color='green'>+8%</font>. <a href='https://seekingalpha.com/symbol/VOC' title='VOC Energy Trust'>VOC</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/VLP' title='Valero Energy Partners LP'>VLP</a> <font color='green'>+7%</font>. <a href='https://seekingalpha.com/symbol/OSN' title='Ossen Innovation Co., Ltd.'>OSN</a> <font color='green'>+6%</font>. <a href='https://seekingalpha.com/symbol/WDFC' title='WD-40 Company'>WDFC</a> <font color='green'>+6%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/XOG' title='Extraction Oil & Gas'>XOG</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/SXT' title='Sensient Technologies Corporation'>SXT</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/JONE' title='Jones Energy, Inc.'>OTC:JONE</a> <font color='red'>-15%</font>. <a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-9%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3399002\" data-linked=\"Energy/Materials  - Top 5 Gainers / Losers as of 2:00 PM (10/19/2018)\" data-tweet=\"$PKD-OLD $PKD $VOC - Energy/Materials - Top 5 Gainers / Losers as of 2:00 PM (10/19/2018) https://seekingalpha.com/news/3399002-energy-materials-top-5-gainers-losers-of-2-00-pm-10-19-2018?source=tweet\" data-url=\"https://seekingalpha.com/news/3399002-energy-materials-top-5-gainers-losers-of-2-00-pm-10-19-2018\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  2:00 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3399063\" data-ts=\"1539971734\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/HOG\" target=\"_blank\">HOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3399063-harley-davidsonminus-2-after-bmo-downgrade-trump-damage-done\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Harley-Davidson -2% after BMO downgrade; Trump &#39;damage has been done&#39;</a></h4><ul>     <li>Harley-Davidson (<a href='https://seekingalpha.com/symbol/HOG' title='Harley-Davidson, Inc.'>HOG</a> <font color='red'>-1.9%</font>) is lower after BMO&nbsp;Capital <a href=\"https://thefly.com/thestreet/realmoney/index.php/HOGid2807054/HOG-HarleyDavidson-downgraded-to-Market-Perform-at-BMO-Capital-on-soft-demand\" target=\"_blank\">downgrades</a> shares to Market Perform from Outperform with a $45 price target, trimmed from $52, saying recent evidence suggests HOG's spat with Pres. Trump is <a href=\"https://www.cnbc.com/2018/10/19/trump-approved-boycott-of-harley-taking-a-toll-as-trade-ins-rise.html\" target=\"_blank\">adding to the company's woes</a>.</li>     <li>BMO's Gerrick Johnson says Harley riders have been trading in their \"hogs\" in increasing numbers as the company fights through a public relations nightmare created when it said it was shifting some production overseas.</li>     <li>\"While Pres. Trump's assessment of HOG's actions in his tweets were often factually inaccurate, the damage has been done,\" Johnson writes. \"Dealers are feeling an impact, and we find that the impact has become more acute over time.\"</li>     <li>Johnson says for the first time in 10 years of covering powersports, he is witnessing a manufacturer develop innovative new products that are significant improvements without seeing an increase in demand.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3399063\" data-linked=\"Harley-Davidson -2% after BMO downgrade; Trump &#39;damage has been done&#39;\" data-tweet=\"$HOG - Harley-Davidson -2% after BMO downgrade; Trump &#39;damage has been done&#39; https://seekingalpha.com/news/3399063-harley-davidsonminus-2-after-bmo-downgrade-trump-damage-done?source=tweet\" data-url=\"https://seekingalpha.com/news/3399063-harley-davidsonminus-2-after-bmo-downgrade-trump-damage-done\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398995\" data-ts=\"1539970510\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PG\" target=\"_blank\">PG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398995-procter-gamble-nowplus-8_1-jpmorgan-boosts-to-overweight\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Procter &amp; Gamble now +8.1%; JPMorgan boosts to Overweight</a></h4><ul>   <li>Procter &amp; Gamble (NYSE:<a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a>) has built on <a href=\"https://seekingalpha.com/news/3398841-p-and-g-gains-4_4-percent-premarket-fiscal-q1-eps-beats-reaffirms-year-guidance\" target=\"_blank\">premarket gains</a> from its strong quarterly report, <font color='green'>rising 8.1%</font> to reach its highest point since late January.</li>    <li>JPMorgan has now upgraded shares to Overweight from Neutral in response to the solid numbers.</li>    <li>The firm's Andrea Teixeira boosted its price target to a round $100 from $82, now implying 15.5% upside from current pricing.</li>    <li>A spring swoon still means that year-to-date price performance is <font color='red'>-12.7%</font>. Shares were <font color='green'>up 8.7%</font> over the past six months.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398995\" data-linked=\"Procter &amp; Gamble now +8.1%; JPMorgan boosts to Overweight\" data-tweet=\"$PG - Procter &amp; Gamble now +8.1%; JPMorgan boosts to Overweight https://seekingalpha.com/news/3398995-procter-gamble-nowplus-8_1-jpmorgan-boosts-to-overweight?source=tweet\" data-url=\"https://seekingalpha.com/news/3398995-procter-gamble-nowplus-8_1-jpmorgan-boosts-to-overweight\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  1:35 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>26&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398988\" data-ts=\"1539968363\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLF\" target=\"_blank\">CLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398988-cleveland-cliffs-ceo-goncalves-berates-analysts-on-conference-call\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland-Cliffs CEO Goncalves berates analysts on conference call</a></h4><ul><li>Today's sharp drop in Cleveland-Cliffs (<a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a> <font color='red'>-5.5%</font>) even after reporting strong increases in <a href=\"https://seekingalpha.com/news/3398854-cleveland-cliffs-misses-0_03-beats-revenue\" target=\"_blank\">Q3 earnings</a> and revenue prompts something of a meltdown by CEO Lourenco Goncalves, who <a href=\"https://www.cnbc.com/2018/10/19/ceo-berates-analysts-you-are-a-disasterthey-will-have-to-commit-suicide.html\" target=\"_blank\">berated analysts</a> during the company's earnings conference call.</li><li>Following the first analyst question, the CEO said: \"It's unbelievable that these big banks still employ this type of  people, you should resign for your lack of knowledge of things... You are a disaster. You are an embarrassment to your parents... If the stock continues to go down based on these kids that play with  computers and somebody else's money, we are going to buy back stock. We  are going to screw this guy so badly that I don't believe that they will  be able to only resign. They will have to commit suicide.\"</li><li>To Goldman Sachs analyst Matthew Korn, who rates CLF as a Hold, Goncalves said, \"you can run but you can't hide.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3398988\" data-linked=\"Cleveland-Cliffs CEO Goncalves berates analysts on conference call\" data-tweet=\"$CLF - Cleveland-Cliffs CEO Goncalves berates analysts on conference call https://seekingalpha.com/news/3398988-cleveland-cliffs-ceo-goncalves-berates-analysts-on-conference-call?source=tweet\" data-url=\"https://seekingalpha.com/news/3398988-cleveland-cliffs-ceo-goncalves-berates-analysts-on-conference-call\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:59 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>164&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398983\" data-ts=\"1539968116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LMFA\" target=\"_blank\">LMFA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398983-bank-ozk-continues-to-top-financial-sector-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank OZK continues to top financial sector losers</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a> <font color='green'>+75%</font>. <a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='green'>+25%</font>. <a href='https://seekingalpha.com/symbol/DXF' title='Dunxin Financial Holdings Limited'>DXF</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/OFG' title='OFG Bancorp'>OFG</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/BCRH' title='Blue Capital Reinsurance Holdings Ltd.'>BCRH</a> <font color='green'>+9%</font>.</li><li><b>Losers: </b><a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/TRUP' title='Trupanion'>TRUP</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/FFBC' title='First Financial Bancorp.'>FFBC</a> <font color='red'>-6%</font>. <a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='red'>-6%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398983\" data-linked=\"Bank OZK continues to top financial sector losers\" data-tweet=\"$LMFA $LMFA $LYL - Bank OZK continues to top financial sector losers https://seekingalpha.com/news/3398983-bank-ozk-continues-to-top-financial-sector-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398983-bank-ozk-continues-to-top-financial-sector-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:55 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398980\" data-ts=\"1539967565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLO\" target=\"_blank\">VLO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398980-oil-and-gas-refiners-plunge-following-valero-deal-imo-rules\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Oil and gas refiners plunge following Valero deal, IMO rules</a></h4><ul>     <li>Shares of oil and gas refiners post sharp losses following <a href=\"https://seekingalpha.com/news/3398737-valero-energy-valero-energy-partners-merge\" target=\"_blank\">merger news</a> from Valero Energy (<a href='https://seekingalpha.com/symbol/VLO' title='Valero Energy Corporation'>VLO</a> <font color='red'>-8.5%</font>) and Valero Energy Partners (<a href='https://seekingalpha.com/symbol/VLP' title='Valero Energy Partners LP'>VLP</a> <font color='green'>+6.7%</font>), which prompted a new <a href=\"https://thefly.com/thestreet/realmoney/index.php/VLO%3bMPCid2806951/VLO%3bMPC-Valero-downgraded-to-Sell-from-Neutral-at-Goldman-Sachs\" target=\"_blank\">Sell rating</a> on VLO from analysts at Goldman Sachs.</li>     <li>Goldman's Neil Mehta downgraded VLO to Sell from Neutral and cut his price target to $102 from $124, forecasting 18% downside to 2019 consensus earnings estimates given the company's lower leverage to inland crude differentials vs. tightening LLS-Maya trends and his reduced outlook for gasoline margins in the next 12 months.</li>     <li>Also likely affecting refiner shares is a <em>WSJ</em> report that the Trump administration is <a href=\"https://www.wsj.com/articles/white-house-seeks-to-slow-rollout-of-rules-for-cleaner-ship-fuels-1539900741\" target=\"_blank\">aiming to slow the rollout</a> of new International Maritime Organization rules to power commercial ships; big U.S. refiners likely would be major beneficiaries from selling more higher-grade fuels.</li>     <li>Cowen analysts say the drop in refiner shares is overdone, as the White House does not have unilateral power to stop IMO 2020 implementation.</li>     <li>In the red: <a href='https://seekingalpha.com/symbol/PBF' title='PBF Energy'>PBF</a> <font color='red'>-8.5%</font>, <a href='https://seekingalpha.com/symbol/HFC' title='HollyFrontier Corp.'>HFC</a> <font color='red'>-5.9%</font>, <a href='https://seekingalpha.com/symbol/MPC' title='Marathon Petroleum Corp.'>MPC</a> <font color='red'>-5.3%</font>, <a href='https://seekingalpha.com/symbol/PSX' title='Phillips 66'>PSX</a> <font color='red'>-5.1%</font>, <a href='https://seekingalpha.com/symbol/DK' title='Delek US Holdings, Inc.'>DK</a> <font color='red'>-3.7%</font>, <a href='https://seekingalpha.com/symbol/CVI' title='CVR Energy, Inc.'>CVI</a> <font color='red'>-3.3%</font>, <a href='https://seekingalpha.com/symbol/CVRR' title='CVR Refining, LP'>CVRR</a> <font color='red'>-2.5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398980\" data-linked=\"Oil and gas refiners plunge following Valero deal, IMO rules\" data-tweet=\"$VLO $VLO $VLP - Oil and gas refiners plunge following Valero deal, IMO rules https://seekingalpha.com/news/3398980-oil-and-gas-refiners-plunge-following-valero-deal-imo-rules?source=tweet\" data-url=\"https://seekingalpha.com/news/3398980-oil-and-gas-refiners-plunge-following-valero-deal-imo-rules\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:46 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>296&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398979\" data-ts=\"1539967309\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAG\" target=\"_blank\">PLAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398979-microcaps-mostly-top-list-of-midday-movers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Microcaps mostly top list of midday movers</a></h4><ul>     <li><strong>Gainers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a> <font color='green'>+331%</font>. <a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+145%</font>. <a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a> <font color='green'>+84%</font>. <a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a> <font color='green'>+61%</font>. <a href='https://seekingalpha.com/symbol/LYL' title='Dragon Victory International Limited'>LYL</a> <font color='green'>+27%</font>. <a href='https://seekingalpha.com/symbol/NDRA' title='Endra Life Sciences Inc'>NDRA</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/DXF' title='Dunxin Financial Holdings Limited'>DXF</a> <font color='green'>+22%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+21%</font>. <a href='https://seekingalpha.com/symbol/TMSR' title='TMSR Holding Co., Ltd.'>TMSR</a> <font color='green'>+19%</font>. <a href='https://seekingalpha.com/symbol/NVMM' title='NOVUME SOLUTIONS INC'>NVMM</a> <font color='green'>+18%</font>.</li>     <li><strong>Losers:&nbsp;</strong><a href='https://seekingalpha.com/symbol/SREV' title='ServiceSource International, Inc.'>SREV</a> <font color='red'>-46%</font>. <a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='red'>-36%</font>. <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-28%</font>. <a href='https://seekingalpha.com/symbol/IFMK' title='iFresh Inc.'>IFMK</a> <font color='red'>-27%</font>. <a href='https://seekingalpha.com/symbol/IGC' title='India Globalization Capital, Inc'>OTC:IGC</a> <font color='red'>-25%</font>. <a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a> <font color='red'>-23%</font>. <a href='https://seekingalpha.com/symbol/CNXN' title='PC Connection, Inc.'>CNXN</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color='red'>-22%</font>. <a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-21%</font>. <a href='https://seekingalpha.com/symbol/CADC' title='China Advanced Construction Materials Group, Inc.'>CADC</a> <font color='red'>-22%</font>.</li>  </ul><div class=\"tiny-share-widget\" data-id=\"3398979\" data-linked=\"Microcaps mostly top list of midday movers\" data-tweet=\"$PLAG $PLAG $NCTY - Microcaps mostly top list of midday movers https://seekingalpha.com/news/3398979-microcaps-mostly-top-list-of-midday-movers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398979-microcaps-mostly-top-list-of-midday-movers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:41 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398978\" data-ts=\"1539967220\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/LLY\" target=\"_blank\">LLY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398978-englands-cost-watchdog-not-on-board-lillys-verzenio-shares-down-1\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">England&#39;s cost watchdog not on board with Lilly&#39;s Verzenio; shares down 1%</a></h4><ul><li>England's National Institute for Health and Care Excellence &#40;NICE&#41;, the advisor to the National Health Service &#40;NHS&#41;&nbsp;on cost and care quality, has issued draft guidance <a href=\"http://www.pharmafile.com/news/519113/nice-rejects-elil-lillys-verzenio-breast-cancer-draft-guidance\" target=\"_blank\">against recommending</a> Eli Lilly's (<a href='https://seekingalpha.com/symbol/LLY' title='Eli Lilly and Company'>LLY</a> <font color='red'>-0.8%</font>) breast cancer med Verzenio (abemaciclib) due to its high cost.</li><li>NICE believes that Verzenio is on par with Pfizer's (<a href='https://seekingalpha.com/symbol/PFE' title='Pfizer Inc.'>PFE</a> <font color='green'>+1.4%</font>) Ibrance (palbociclib) and Novartis' (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+1.2%</font>) Kisqali (ribociclib) for HR+/HER2- locally advanced/metastatic breast cancer, both of which are already on the NHS formulary.</li><li>Public comment is open until November 8.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398978\" data-linked=\"England&#39;s cost watchdog not on board with Lilly&#39;s Verzenio; shares down 1%\" data-tweet=\"$LLY $LLY $PFE - England&#39;s cost watchdog not on board with Lilly&#39;s Verzenio; shares down 1% https://seekingalpha.com/news/3398978-englands-cost-watchdog-not-on-board-lillys-verzenio-shares-down-1?source=tweet\" data-url=\"https://seekingalpha.com/news/3398978-englands-cost-watchdog-not-on-board-lillys-verzenio-shares-down-1\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:40 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398977\" data-ts=\"1539967185\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MCD\" target=\"_blank\">MCD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398977-mcdonalds-wendys-get-buys-in-gordon-haskett-restaurant-look\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">McDonald&#39;s, Wendy&#39;s get Buys in Gordon Haskett restaurant look</a></h4><ul>   <li>McDonald's (<a href=\"http://seekingalpha.com/symbol/MCD\" target=\"_blank\">MCD</a> <font color='green'>+0.3%</font>) and Wendy's (<a href=\"http://seekingalpha.com/symbol/WEN\" target=\"_blank\">WEN</a> <font color='green'>+0.2%</font>) are among new Buys in mass initiation of coverage on the restaurant sector by research firm Gordon Haskett.</li>    <li>They're joined in bullish ratings by Bloomin' Brands (<a href=\"http://seekingalpha.com/symbol/BLMN\" target=\"_blank\">BLMN</a> <font color='red'>-0.9%</font>), Dave &amp; Buster's (<a href=\"http://seekingalpha.com/symbol/PLAY\" target=\"_blank\">PLAY</a> <font color='red'>-2.9%</font>) and Wingstop (<a href=\"http://seekingalpha.com/symbol/WING\" target=\"_blank\">WING</a> <font color='red'>-0.7%</font>).</li>    <li>The firm's $185 target for <a href='https://seekingalpha.com/symbol/MCD' title='McDonald&#39;s Corporation'>MCD</a> implies 10.5% upside; a $20 target on Wendy's implies 17.4% upside; the $23 price target on Bloomin' Brands implies 18% upside; a $70 target on <a href='https://seekingalpha.com/symbol/PLAY' title='Dave & Buster&#39;s Entertainment, Inc.'>PLAY</a> implies 20% upside; and the firm sees 14% upside for Wingstop with a target of $81.</li>    <li>On the other side of the equation, analysts Jeff Farmer and Robert Mullins started Underperform ratings on four chains: BJ's Restaurants (<a href=\"http://seekingalpha.com/symbol/BJRI\" target=\"_blank\">BJRI</a> <font color='red'>-1.9%</font>), Chipotle (<a href=\"http://seekingalpha.com/symbol/CMG\" target=\"_blank\">CMG</a> <font color='red'>-0.8%</font>), Darden (<a href=\"http://seekingalpha.com/symbol/DRI\" target=\"_blank\">DRI</a> <font color='red'>-2.8%</font>) and Texas Roadhouse (<a href=\"http://seekingalpha.com/symbol/TXRH\" target=\"_blank\">TXRH</a> <font color='red'>-1.3%</font>).</li>    <li>The analysts are Neutral on Brinker (<a href=\"http://seekingalpha.com/symbol/EAT\" target=\"_blank\">EAT</a> <font color='red'>-2%</font>), Cheesecake Factory (<a href=\"http://seekingalpha.com/symbol/CAKE\" target=\"_blank\">CAKE</a> <font color='red'>-1.3%</font>), Cracker Barrel (<a href=\"http://seekingalpha.com/symbol/CBRL\" target=\"_blank\">CBRL</a> <font color='green'>+1.5%</font>), Dunkin' (<a href=\"http://seekingalpha.com/symbol/DNKN\" target=\"_blank\">DNKN</a> <font color='red'>-0.6%</font>), Jack in the Box (<a href=\"http://seekingalpha.com/symbol/JACK\" target=\"_blank\">JACK</a> <font color='red'>-2%</font>), Red Robin (<a href=\"http://seekingalpha.com/symbol/RRGB\" target=\"_blank\">RRGB</a> <font color='red'>-5.3%</font>) and Yum Brands (<a href=\"http://seekingalpha.com/symbol/YUM\" target=\"_blank\">YUM</a> <font color='red'>-0.2%</font>).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398880-keybanc-sees-weak-sales-mcdonalds-wendys\" target=\"_blank\">KeyBanc sees weak sales for McDonald's, Wendy's</a> (Oct. 19 2018)</li>   </ul><div class=\"tiny-share-widget\" data-id=\"3398977\" data-linked=\"McDonald&#39;s, Wendy&#39;s get Buys in Gordon Haskett restaurant look\" data-tweet=\"$MCD $MCD $PLAY - McDonald&#39;s, Wendy&#39;s get Buys in Gordon Haskett restaurant look https://seekingalpha.com/news/3398977-mcdonalds-wendys-get-buys-in-gordon-haskett-restaurant-look?source=tweet\" data-url=\"https://seekingalpha.com/news/3398977-mcdonalds-wendys-get-buys-in-gordon-haskett-restaurant-look\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:39 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398976\" data-ts=\"1539966713\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/\" target=\"_blank\"></a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398976-tech-lunch-break-semis-break-sectors-stride\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tech lunch break: Semis break the sector&#39;s stride</a></h4><ul><li>The tech sector is keeping pace with the broader market today with the exception of semiconductors. The Technology Select Sector SPDR Fund (NYSEARCA:<a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>) is&nbsp;<font color='green'>up 0.53%</font>, the S&amp;P 500 IT Index is&nbsp;down&nbsp;<font color='green'>0.55%</font>, and the Philadelphia Semiconductor Index is&nbsp;<font color='red'>down 1%</font>&nbsp;compared to the<font color='green'>&nbsp;0.6%</font>&nbsp;gain for the S&amp;P 500.</li><li>Services: PayPal&nbsp;<font color='green'>+8% gets a boost</font>&nbsp;from its consensus beating Q3 report, which mentioned weak eBay&nbsp;<font color='red'>-9.4%</font>&nbsp;gross merchandise value that led to a downgrade.&nbsp; ADS slips&nbsp;<font color='red'>-2.3%&nbsp;</font>as it gives up yesterday&rsquo;s capital return gains.</li><li>Software: Pivotal Software&nbsp;<font color='green'>+3%</font>&nbsp;leads after a Wedbush start at Outperform. DocuSign&nbsp;<font color='red'>-9.4%</font>&nbsp;feels pressure from its Wedbush initiation at Neutral and next week&rsquo;s lock-up expiration. Atlassian&nbsp;<font color='red'>-10.7%&nbsp;</font>drops despite reporting a Q1 beat with strong guidance.</li><li>Hardware: Apple&nbsp;<font color='green'>+1%</font>&nbsp;leads higher on news of an October 30 launch event expected to include new iPads and MacBook Airs.</li><li>Semis: AMD&nbsp;<font color='red'>-6.5%</font>&nbsp;presses down after it was started at Sell and takes Intel&nbsp;<font color='red'>-2.1%&nbsp;</font>(and much of the semi industry) down with it.</li><li>Related broad tech ETFs: <a href='https://seekingalpha.com/symbol/XLK' title='Technology Select Sector SPDR ETF'>XLK</a>, <a href='https://seekingalpha.com/symbol/VGT' title='Vanguard Information Technology ETF'>VGT</a>, <a href='https://seekingalpha.com/symbol/TECL' title='Direxion Technology Bull 3x Shares ETF'>TECL</a>, <a href='https://seekingalpha.com/symbol/FTEC' title='Fidelity MSCI Information Technology Index ETF'>FTEC</a>, <a href='https://seekingalpha.com/symbol/IYW' title='iShares U.S. Technology ETF'>IYW</a>, <a href='https://seekingalpha.com/symbol/ROM' title='ProShares Ultra Technology ETF'>ROM</a>, <a href='https://seekingalpha.com/symbol/QTEC' title='First Trust NASDAQ-100-Tech Index ETF'>QTEC</a>, <a href='https://seekingalpha.com/symbol/RYT' title='Invesco S&P 500 Equal Weight Technology ETF'>RYT</a>, <a href='https://seekingalpha.com/symbol/FNG' title='AdvisorShares New Tech and Media ETF'>FNG</a>, <a href='https://seekingalpha.com/symbol/TECS' title='Direxion Technology Bear 3x Shares ETF'>TECS</a>, <a href='https://seekingalpha.com/symbol/IGM' title='iShares North American Tech ETF'>IGM</a>, <a href='https://seekingalpha.com/symbol/FXL' title='First Trust Tech AlphaDEX ETF'>FXL</a>, <a href='https://seekingalpha.com/symbol/XNTK' title='SPDR NYSE Technology ETF'>XNTK</a>, <a href='https://seekingalpha.com/symbol/REW' title='ProShares UltraShort Technology ETF'>REW</a>, <a href='https://seekingalpha.com/symbol/JHMT' title='John Hancock Multifactor Technology ETF'>JHMT</a>, <a href='https://seekingalpha.com/symbol/XITK' title='SPDR Innovative Technology ETF'>XITK</a></li><li>Top tech stories from yesterday afternoon and this morning:</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398426-alliance-data-plus-3_1-percent-premarket-q3-eps-beats-strong-card-services\" target=\"_blank\">Alliance Data +3.1% in premarket as Q3 EPS beats on strong card services</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398693-atlassian-minus-6-percent-despite-q1-beat-strong-guidance\" target=\"_blank\">Atlassian -6% despite Q1 beat and strong guidance</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398842-stifel-cuts-ebay-weak-q3-gmv-shares-minus-4-percent\" target=\"_blank\">Stifel cuts eBay on weak Q3 GMV; shares -4%</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398886-paypal-gains-8_1-percent-q3-beat-btigs-venmo-based-upgrade\" target=\"_blank\">PayPal gains 8.1% after after Q3 beat, BTIG's Venmo-based upgrade</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398953-docusign-wedbush-neutral-start-upcoming-lock-expiration\" target=\"_blank\">DocuSign down on Wedbush Neutral start, upcoming lock-up expiration</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398848-wedbush-starts-pivotal-outperform-subscription-growth\" target=\"_blank\">Wedbush starts Pivotal at Outperform on subscription growth</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398568-apple-sets-oct-30-event-likely-feature-ipads-macs\" target=\"_blank\">Apple sets Oct. 30 event likely to feature iPads, Macs</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398758-apple-gets-street-high-310-price-target-wedbush\" target=\"_blank\">Apple gets Street-high $310 price target from Wedbush</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398961-amd-minus-2_4-percent-new-sell-rating\" target=\"_blank\">AMD -2.4% on new Sell rating</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398976\" data-linked=\"Tech lunch break: Semis break the sector&#39;s stride\" data-tweet=\"$XLK $VGT $TECL - Tech lunch break: Semis break the sector&#39;s stride https://seekingalpha.com/news/3398976-tech-lunch-break-semis-break-sectors-stride?source=tweet\" data-url=\"https://seekingalpha.com/news/3398976-tech-lunch-break-semis-break-sectors-stride\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:31 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>3&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398974\" data-ts=\"1539966161\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AXP\" target=\"_blank\">AXP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398974-american-express-gains-after-q3-earnings-beat-guidance-boost-paypal-pact\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">American Express gains after Q3 earnings beat, guidance boost, PayPal pact</a></h4><ul><li>American Express (NYSE:<a href='https://seekingalpha.com/symbol/AXP' title='American Express Company'>AXP</a>)&nbsp;<font color='green'>rises 3.7%</font>&nbsp;after Q3 beat average analysts' estimate and credit-card company boost its guidance for the year. The good earnings news came on the same day that AXP announced an expanded partnership with PayPal in digital payments.</li><li>Q3 marketing-related costs, including member rewards, fell from Q2,&nbsp;says David Russell, vice president of content strategy at TradeStation.&nbsp;Meanwhile, the company boosted earnings guidance with only a small increase in its revenue outlook.</li><li>\"Both of those facts suggest management has successfully gained traction with new clients,\" Russell says.\"They seem to be executing on their growth plan and now can reap benefits from those investments.\"</li><li>Lower operating expenses also helps margins going forward, he added.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398680-american-express-q3-revenue-card-member-spending-loans-fees\" target=\"_blank\">More on American Express Q3: Revenue up on card member spending, loans, fees</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398648-american-express-beats-0_11-beats-revenue\" target=\"_blank\">American Express beats by $0.11, beats on revenue</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398612-american-express-paypal-expand-partnership-improve-digital-payments\" target=\"_blank\">American Express, PayPal expand partnership to improve digital payments</a> (Oct. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398974\" data-linked=\"American Express gains after Q3 earnings beat, guidance boost, PayPal pact\" data-tweet=\"$AXP - American Express gains after Q3 earnings beat, guidance boost, PayPal pact https://seekingalpha.com/news/3398974-american-express-gains-after-q3-earnings-beat-guidance-boost-paypal-pact?source=tweet\" data-url=\"https://seekingalpha.com/news/3398974-american-express-gains-after-q3-earnings-beat-guidance-boost-paypal-pact\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:22 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398973\" data-ts=\"1539965904\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RHHBY\" target=\"_blank\">RHHBY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398973-fda-oks-new-use-for-roches-rituxan-shares-up-3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA OKs new use for Roche&#39;s Rituxan; shares up  3%</a></h4><ul><li>The FDA <a href=\"https://seekingalpha.com/pr/17306367-fda-approves-label-update-genentech-s-rituxan-rituximab-two-rare-forms-vasculitis\" target=\"_blank\">approves </a>the use of Roche (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a> <font color='green'>+2.9%</font>) unit Genentech's Rituxan (rituximab) for two rare forms of vasculitis (blood vessel inflammation), granulomatosis with polyangiitis and microscopic polyangiitis, in adult patients who have achieved disease control with induction treatment.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398973\" data-linked=\"FDA OKs new use for Roche&#39;s Rituxan; shares up  3%\" data-tweet=\"$RHHBY - FDA OKs new use for Roche&#39;s Rituxan; shares up 3% https://seekingalpha.com/news/3398973-fda-oks-new-use-for-roches-rituxan-shares-up-3?source=tweet\" data-url=\"https://seekingalpha.com/news/3398973-fda-oks-new-use-for-roches-rituxan-shares-up-3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:18 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398972\" data-ts=\"1539965846\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/REN\" target=\"_blank\">REN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398972-kimmeridge-tells-resolute-energy-to-pursue-sale-merger\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kimmeridge tells Resolute Energy to pursue sale or merger</a></h4><ul>     <li>Resolute Energy (<a href='https://seekingalpha.com/symbol/REN' title='Resolute Energy Corporation'>REN</a> <font color='green'>+2%</font>) moves higher after shareholder Kimmeridge Energy tells the company's board that it is <a href=\"https://www.wsj.com/articles/frustrated-investors-want-frackers-to-consolidate-1539958426\" target=\"_blank\">calling for changes</a>, saying REN has failed to follow through on a strategic review to explore a merger or potential asset sale announced in May.</li>     <li>Kimmeridge, which owns 9.7% of REN's shares, says in a <a href=\"https://www.sec.gov/Archives/edgar/data/1469510/000090266418003790/exhibita.htm\" target=\"_blank\">letter</a> that it may seek to install new board members if the company fails to heed its suggestions.</li>     <li>The P-E firm says REN is too small to properly develop its assets and accuses company management of enriching itself while pursuing growth over returns.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398972\" data-linked=\"Kimmeridge tells Resolute Energy to pursue sale or merger\" data-tweet=\"$REN - Kimmeridge tells Resolute Energy to pursue sale or merger https://seekingalpha.com/news/3398972-kimmeridge-tells-resolute-energy-to-pursue-sale-merger?source=tweet\" data-url=\"https://seekingalpha.com/news/3398972-kimmeridge-tells-resolute-energy-to-pursue-sale-merger\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:17 PM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398969\" data-ts=\"1539965524\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SXT\" target=\"_blank\">SXT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398969-sensient-technologies-slips-14-on-q3-revenue-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Sensient Technologies slips 14% on Q3 revenue miss</a></h4><ul><li>Sensient Technologies (<a href='https://seekingalpha.com/symbol/SXT' title='Sensient Technologies Corporation'>SXT</a> <font color='red'>-14.1%</font>) reported Q3 revenue decrease of 3.1% Y/Y to $324.7M. Foreign currency translation decreased revenue and Adj. EPS by ~2%.</li><li>Segment revenues: Flavors &amp; Fragrances $184.39M (-5.9% Y/Y); Color $134.96M (+1.3% Y/Y) and Asia Pacific $31.27M (-4.4% Y/Y).</li><li>Q3 Adj. operating margin&nbsp;<font color='red'>declined 175 bps</font>&nbsp;to 14.7%.</li><li>SG&amp;A expenses decreased by 7.7% Y/Y to $65.31M.</li><li>Net cash provided by operating activities for the nine months ended was $8.86M, compared to $22.16M a year ago.</li><li>Company has cash and cash equivalents&nbsp; of $36.76M as of September 30, 2018.</li><li><strong>4Q18 Guidance:</strong> Company expects the impact of the recent acquisition to reduce 4Q18 EPS by ~$0.01; and Adj. EPS by ~ $0.10.</li><li><strong>FY18 Guidance</strong>: The Company expects FY18 Adj. EPS to be slightly below the range previously provided ($3.6-3.7).</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398813-sensient-technologies-eps-line-misses-revenue\" target=\"_blank\">Sensient Technologies EPS in-line, misses on revenue</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398747-sensient-technologies-declares-0_36-dividend\" target=\"_blank\">Sensient Technologies declares $0.36 dividend</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398969\" data-linked=\"Sensient Technologies slips 14% on Q3 revenue miss\" data-tweet=\"$SXT - Sensient Technologies slips 14% on Q3 revenue miss https://seekingalpha.com/news/3398969-sensient-technologies-slips-14-on-q3-revenue-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3398969-sensient-technologies-slips-14-on-q3-revenue-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:12 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398971\" data-ts=\"1539965365\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TGODF\" target=\"_blank\">TGODF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398971-ianthus-buying-mpx-bioceutical-cannabis-wrap\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">iAnthus buying MPX Bioceutical - Cannabis wrap</a></h4><ul><li><a href=\"https://www.marketwatch.com/story/cannabis-stocks-mixed-as-investors-digest-the-latest-deals-and-capital-raises-2018-10-19\" target=\"_blank\">via Marketwatch</a></li><li>The Green Organic Dutchman Holdings (<a href='https://seekingalpha.com/symbol/TGODF' title='Green Organic Dutchman Holdings Ltd.'>OTCQX:TGODF</a> <font color='red'>-7.5%</font>) closed a C$76M capital raise to help fund expansion plans.</li><li>iAnthus Capital Holdings (<a href='https://seekingalpha.com/symbol/ITHUF' title='iAnthus Capital Holdings, Inc.'>OTCQX:ITHUF</a> <font color='red'>-3.2%</font>) is <a href=\"https://seekingalpha.com/pr/17305140-ianthus-mpx-bioceutical-announce-transformational-combination-expands-u-s-footprint-10-states\" target=\"_blank\">purchasing</a> MPX Bioceutical (<a href='https://seekingalpha.com/symbol/MPXEF' title='MPX Bioceutical Corp.'>OTCQX:MPXEF</a> <font color='red'>-1.8%</font>) in an all-stock deal valued at $835M. The combined company will have cannabis licenses in 10 U.S. states, with 56 retail outlets and 14 growing/processing facilities. The 10 states are seen generating more than $16B in annual cannabis sales by 2022, according to the release. Cormark Securities is a fan, boosting its price target to C$9.25 from C$8.25.</li><li>Aurora Cannabis (ACBFF <font color='green'>+1%</font>) has more shopkeeping units available than peer, says GMP's Martin Landry.</li><li>Related names: <a href='https://seekingalpha.com/symbol/CGC' title='Canopy Growth Corporation'>CGC</a>, <a href='https://seekingalpha.com/symbol/MJNA' title='Medical Marijuana, Inc.'>OTCPK:MJNA</a>, ACBFF, <a href='https://seekingalpha.com/symbol/GWPH' title='GW Pharmaceuticals plc'>GWPH</a>, <a href='https://seekingalpha.com/symbol/PHOT' title='Growlife Inc.'>OTCQB:PHOT</a>, <a href='https://seekingalpha.com/symbol/CBIS' title='Cannabis Science, Inc.'>OTCPK:CBIS</a>, APHQF, <a href='https://seekingalpha.com/symbol/TRTC' title='Terra Tech Corp.'>OTCQX:TRTC</a>, <a href='https://seekingalpha.com/symbol/CRON' title='Cronos Group, Inc.'>CRON</a>, <a href='https://seekingalpha.com/symbol/CANN' title='General Cannabis Corp.'>OTCQX:CANN</a>, <a href='https://seekingalpha.com/symbol/ERBB' title='American Green, Inc.'>OTCPK:ERBB</a>, <a href='https://seekingalpha.com/symbol/GRNH' title='GreenGro Technologies, Inc.'>OTCPK:GRNH</a>, <a href='https://seekingalpha.com/symbol/PMCB' title='PharmaCyte Biotech, Inc.'>OTCQB:PMCB</a>, <a href='https://seekingalpha.com/symbol/CVSI' title='CV Sciences, Inc.'>OTCQB:CVSI</a>, <a href='https://seekingalpha.com/symbol/FITX' title='Creative Edge Nutrition, Inc.'>OTC:FITX</a>, <a href='https://seekingalpha.com/symbol/MJ' title='ETFMG Alternative Harvest ETF'>MJ</a>, <a href='https://seekingalpha.com/symbol/HEMP' title='Hemp, Inc.'>OTCPK:HEMP</a>, <a href='https://seekingalpha.com/symbol/CBDS' title='Cannabis Sativa, Inc.'>OTCQB:CBDS</a>, <a href='https://seekingalpha.com/symbol/BLOZF' title='Cannabix Technologies Inc.'>OTCPK:BLOZF</a>, <a href='https://seekingalpha.com/symbol/KSHB' title='KushCo Holdings, Inc.'>OTCQB:KSHB</a>, <a href='https://seekingalpha.com/symbol/MSRT' title='MassRoots, Inc.'>OTCQB:MSRT</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3398971\" data-linked=\"iAnthus buying MPX Bioceutical - Cannabis wrap\" data-tweet=\"$TGODF $TGODF $ITHUF - iAnthus buying MPX Bioceutical - Cannabis wrap https://seekingalpha.com/news/3398971-ianthus-buying-mpx-bioceutical-cannabis-wrap?source=tweet\" data-url=\"https://seekingalpha.com/news/3398971-ianthus-buying-mpx-bioceutical-cannabis-wrap\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:09 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>66&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398970\" data-ts=\"1539965330\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BT\" target=\"_blank\">BT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398970-report-bt-offers-ceo-job-to-worldpays-jansen\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Report: BT offers CEO job to Worldpay&#39;s Jansen</a></h4><ul>   <li>BT Group (<a href=\"http://seekingalpha.com/symbol/BT\" target=\"_blank\">BT</a> <font color='green'>+1.6%</font>) has offered its CEO job to Philip Jansen, chief of Worldpay, Bloomberg reports, but it's unclear whether he'll accept.</li>    <li>The <i>Daily Mail</i> reported earlier that Ronan Dunne, formerly CEO of O2 and currently an SVP at Verizon, wasn't looking for the job. Meanwhile, another candidate, Tele2's Allison Kirkby, was named the new CEO at Denmark's TDC.</li>    <li>Embattled BT chief Gavin Patterson said in June that he's exiting the post.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398970\" data-linked=\"Report: BT offers CEO job to Worldpay&#39;s Jansen\" data-tweet=\"$BT - Report: BT offers CEO job to Worldpay&#39;s Jansen https://seekingalpha.com/news/3398970-report-bt-offers-ceo-job-to-worldpays-jansen?source=tweet\" data-url=\"https://seekingalpha.com/news/3398970-report-bt-offers-ceo-job-to-worldpays-jansen\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:08 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398965\" data-ts=\"1539965028\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PETZ\" target=\"_blank\">PETZ</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398965-new-age-beverages-among-consumer-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">New Age Beverages among consumer losers</a></h4><ul><li><b>Gainers:&nbsp;</b><a href='https://seekingalpha.com/symbol/PETZ' title='TDH Holdings, Inc.'>PETZ</a> <font color='green'>+40%</font>. <a href='https://seekingalpha.com/symbol/FTFT' title='Future Fintech Group Inc'>FTFT</a> <font color='green'>+22%</font>.&nbsp;&nbsp;<a href='https://seekingalpha.com/symbol/SGOC' title='SGOCO Techn'>SGOC</a>&nbsp;<font color='green'>+17%.&nbsp;</font><a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='green'>+15%</font>. <a href='https://seekingalpha.com/symbol/FFHL' title='Fuwei Films &#40;Holdings&#41; Co., Ltd.'>FFHL</a> <font color='green'>+9%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/VFC' title='V.F. Corporation'>VFC</a> <font color='red'>-8%</font>. <a href='https://seekingalpha.com/symbol/MINI' title='Mobile Mini, Inc.'>MINI</a> <font color='red'>-7%</font>. <a href='https://seekingalpha.com/symbol/NBEV' title='New Age Beverages Corporation'>NBEV</a> <font color='red'>-5%</font>. <a href='https://seekingalpha.com/symbol/PYX' title='Pyxus International, Inc.'>PYX</a> <font color='red'>-5%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398965\" data-linked=\"New Age Beverages among consumer losers\" data-tweet=\"$PETZ $PETZ $FTFT - New Age Beverages among consumer losers https://seekingalpha.com/news/3398965-new-age-beverages-among-consumer-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398965-new-age-beverages-among-consumer-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 12:03 PM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398962\" data-ts=\"1539964679\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EYPT\" target=\"_blank\">EYPT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398962-fda-nod-for-eyepoints-yutiq-eye-implant-fails-to-lift-shares-down-almost-third-since-approval\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">FDA nod for EyePoint&#39;s Yutiq eye implant fails to lift shares, down almost a third since approval</a></h4><ul><li>EyePoint Pharmaceuticals (<a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a> <font color='red'>-12.9%</font>) continues its slide despite FDA approval earlier this week for YUTIQ (fluocinolone acetonide intravitreal implant) for the treatment of chronic non-infectious uveitis. Shares have sold off&nbsp;<font color='red'>32%</font>&nbsp;since touching $3.78 on Tuesday.</li><li>Uber-bull H.C. Wainwright <a href=\"https://www.smarteranalyst.com/analyst-insights/h-c-wainwright-reiterates-upbeat-view-eyepoint-pharmaceuticals-eypt-stock-back-fda-approval/\" target=\"_blank\">believes </a>the selloff is misguided (BUY/$4.50) considering that it is similar to Alimera Sciences' (<a href='https://seekingalpha.com/symbol/ALIM' title='Alimera Sciences, Inc.'>ALIM</a> <font color='green'>+2.6%</font>) ILUVIEN (fluocinolone acetonide intravitreal implant), approved by the FDA in September 2014 for diabetic macular edema. Analyst Raghuram Selvaraju says YUTIQ could generate $100M in yearly sales, although the projected timeframe for achieving this is unclear.</li><li>Alimera's ILUVIEN generated $10.9M in sales in Q2, up a modest 5% yoy, despite being launched almost four years ago in the U.S. Q2 sales in the U.S. were ~$8M, down 1% from a year ago due to lower distributor orders. Its European application for non-infectious uveitis was filed in January.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397226-fda-approves-eyepoint-pharmaceuticals-yutiq-0_18-mg\" target=\"_blank\">FDA approves EyePoint Pharmaceuticals' YUTIQ 0.18 mg</a> (Oct. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3321241-alimeras-european-application-expanded-use-iluvien-review\" target=\"_blank\">Alimera's European application for expanded use of Iluvien under review</a> (Jan. 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398962\" data-linked=\"FDA nod for EyePoint&#39;s Yutiq eye implant fails to lift shares, down almost a third since approval\" data-tweet=\"$EYPT $EYPT $ALIM - FDA nod for EyePoint&#39;s Yutiq eye implant fails to lift shares, down almost a third since approval https://seekingalpha.com/news/3398962-fda-nod-for-eyepoints-yutiq-eye-implant-fails-to-lift-shares-down-almost-third-since-approval?source=tweet\" data-url=\"https://seekingalpha.com/news/3398962-fda-nod-for-eyepoints-yutiq-eye-implant-fails-to-lift-shares-down-almost-third-since-approval\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:57 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>10&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398961\" data-ts=\"1539964305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/AMD\" target=\"_blank\">AMD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398961-amdminus-2_4-on-new-sell-rating\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">AMD -2.4% on new Sell rating</a></h4><ul><li>        New Street Research <a href=\"https://www.streetinsider.com/Analyst+Comments/UPDATE%3A+New+Street+Research+Starts+AMD+%28AMD%29+at+Sell/14722876.html\" target=\"_blank\">initiates</a> AMD (NASDAQ:<a href='https://seekingalpha.com/symbol/AMD' title='Advanced Micro Devices, Inc.'>AMD</a>) at Sell with an $18 price target, a 32% downside to yesterday&rsquo;s close.</li><li>               AMD has gone on a wild ride in recent months as the company first looked poised to benefit from Intel&rsquo;s 10nm delay but then fell when Intel and a research firm suggested a speedier timeline.&nbsp;&nbsp;</li><li>               AMD shares are&nbsp;<font color='red'>down 2.4%</font>&nbsp;to $25.97. Shares have dropped&nbsp;<font color='red'>14.7%</font>&nbsp;in the past month but are&nbsp;<font color='green'>up 61.3%</font>&nbsp;in the quarter and&nbsp;<font color='green'>159%</font>&nbsp;YTD.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3393776-amd-minus-4_5-percent-intels-10nm-supply-update\" target=\"_blank\">AMD -4.5% on Intel's 10nm supply update</a> (Sept. 28)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394635-intel-gains-amd-plunges-analyst-predicts-faster-10nm-ramp\" target=\"_blank\">Intel gains, AMD plunges as analyst predicts faster 10nm ramp</a> (Oct. 2)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398961\" data-linked=\"AMD -2.4% on new Sell rating\" data-tweet=\"$AMD - AMD -2.4% on new Sell rating https://seekingalpha.com/news/3398961-amdminus-2_4-on-new-sell-rating?source=tweet\" data-url=\"https://seekingalpha.com/news/3398961-amdminus-2_4-on-new-sell-rating\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>194&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398959\" data-ts=\"1539964065\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/QIWI\" target=\"_blank\">QIWI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398959-qiwi-rises-3_3-after-first-bank-joins-sovest-multi-bank-platform\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Qiwi rises 3.3% after first bank joins its Sovest multi-bank platform</a></h4><ul><li>Qiwi (NASDAQ:<a href='https://seekingalpha.com/symbol/QIWI' title='QIWI plc'>QIWI</a>)&nbsp;<font color='green'>advances 3.3%</font>&nbsp;after Russian bank AK Bars Bank<a href=\"https://seekingalpha.com/pr/17305956-qiwi-launches-sovest-multi-bank-platform\" target=\"_blank\"> joins as the first partner</a> in Qiwi's Sovest multi-bank platform</li><li>Sovest, the first pay-by-installment card project in Russia, started in late 2006 and currently has a partner network encompassing 50,000 locations in 2,300 cities across Russia.</li><li>Under the multi-banking model, Sovest will operate the platform, taking care of client acquisition, card distribution as well as brand development and marketing, while partner banks will be responsible for loan origination, client scoring, and collection.</li><li>Sovest plans to start issuing AK Bars cards this month with a dedicated loan portfolio of up to RUB 3.5B in the first year of the partnership.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3383448-qiwi-adjusts-2018-guidance-tochka-rocketbank-agreements\" target=\"_blank\">Qiwi adjusts 2018 guidance for Tochka, Rocketbank agreements</a> (Aug. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398959\" data-linked=\"Qiwi rises 3.3% after first bank joins its Sovest multi-bank platform\" data-tweet=\"$QIWI - Qiwi rises 3.3% after first bank joins its Sovest multi-bank platform https://seekingalpha.com/news/3398959-qiwi-rises-3_3-after-first-bank-joins-sovest-multi-bank-platform?source=tweet\" data-url=\"https://seekingalpha.com/news/3398959-qiwi-rises-3_3-after-first-bank-joins-sovest-multi-bank-platform\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398958\" data-ts=\"1539964020\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOG\" target=\"_blank\">XOG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398958-extraction-oil-gasminus-12-preliminary-outlook-disappoints\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Extraction Oil &amp; Gas -12% as preliminary outlook disappoints</a></h4><ul>     <li>Extraction Oil &amp; Gas (<a href='https://seekingalpha.com/symbol/XOG' title='Extraction Oil & Gas'>XOG</a> <font color='red'>-12.7%</font>) plunges to a 52-week low after issuing <a href=\"https://seekingalpha.com/pr/17305745-extraction-oil-and-gas-inc-provides-operations-guidance-update\" target=\"_blank\">FY 2018 production guidance</a> of 74K-75K boe/day, including 39K-40K bbl/day of crude oil, from a previous outlook of 87K-93K boe/day; the new forecast still represents 44% growth in total equivalent production and 50% more crude oil production Y/Y.</li>     <li>For Q3, XOG estimates average net sales volumes of 75.7K boe/day, including 39.3K bbl/day of crude  oil.</li>     <li>XOG maintains its FY 2018 capex guidance of $890M-$990M, including $770M-$840M of drilling and completion, but lowers its FY 2019 D&amp;C capital spending program to $650M-$700M and sees a 15% Y/Y increase in crude oil production.</li>     <li>XOG says it had expected DCP Midstream&rsquo;s (NYSE:<a href='https://seekingalpha.com/symbol/DCP' title='DCP Midstream'>DCP</a>) Plant 10 \"would provide much more relief than what we are seeing, and the continued tightness severely impacted the production growth ramp that was expected\" in Q3.</li><li>XOG says it is \"not optimistic\" that DCP's next plant, scheduled to come in Q2 2019, will ease tightness in the northern part of the Wattenberg field; as such, XOG says it will focus nearly all&nbsp; 2019 D&amp;C operations in areas serviced by other midstream providers..</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398958\" data-linked=\"Extraction Oil &amp; Gas -12% as preliminary outlook disappoints\" data-tweet=\"$XOG $XOG $DCP - Extraction Oil &amp; Gas -12% as preliminary outlook disappoints https://seekingalpha.com/news/3398958-extraction-oil-gasminus-12-preliminary-outlook-disappoints?source=tweet\" data-url=\"https://seekingalpha.com/news/3398958-extraction-oil-gasminus-12-preliminary-outlook-disappoints\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398956\" data-ts=\"1539963399\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EEFT\" target=\"_blank\">EEFT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398956-euronet-worldwideplus-2_8-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Euronet Worldwide +2.8% post Q3 results</a></h4><ul><li>Euronet Worldwide (<a href='https://seekingalpha.com/symbol/EEFT' title='Euronet Worldwide, Inc.'>EEFT</a> <font color='green'>+2.8%</font>)&nbsp;reports <a href=\"https://seekingalpha.com/pr/17305675-exponent-reports-third-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">Q3</a>&nbsp;revenue growth of 12% Y/Y to $714.5M, of which EFT Processing was 261.7M (+16% Y/Y); Epay 185.4M (+1% Y/Y) &amp; Money Transfer of 268.4M (+18% Y/Y).</li><li>Transactions: Total were 1.02B (+10% Y/Y); EFT Processing 711M (+16% Y/Y); Epay 284M (-3% Y/Y) &amp; Money Transfer 27.8M (+16% Y/Y).</li><li>Operating margin: Total operating&nbsp;<font color='green'>increased 278 bps</font>&nbsp;to 21.1%; EFT Processing&nbsp;<font color='green'>increased 383 bps</font>&nbsp;to 42.2%; Epay&nbsp;<font color='green'>increased 33 bps</font>&nbsp;to 8.5% &amp; Money Transfer&nbsp;<font color='green'>increased 213 bps</font>&nbsp;to 12.8%.</li><li>Adj. EBITDA margin: Total<font color='green'>&nbsp;increased 259 bps</font>&nbsp;to 25.4%; EFT Processing<font color='green'>&nbsp;increased 367 bps</font>&nbsp;to 48.6%; Epay&nbsp;<font color='red'>declined 1 bps</font>&nbsp;to 9.9% &amp; Money Transfer<font color='green'>&nbsp;increased 182 bps</font>&nbsp;to 15.7%.</li><li>Q3 money transfers grew 16% Y/Y and non-transfer transactions, such as currency exchange and check cashing, grew 22% Y/Y, resulting in total transaction growth of 16% Y/Y.</li><li>Cash on hand was&nbsp;$1.13B, total debt was $889M, debt primarily as a result of revolver repayments due to lower seasonal ATM cash requirements.</li><li><b>Q4 Outlook:</b>&nbsp;Adj. EPS ~$1.27.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398761-euronet-beats-0_06-revenue-line\" target=\"_blank\">Euronet beats by $0.06,  revenue in-line</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398956\" data-linked=\"Euronet Worldwide +2.8% post Q3 results\" data-tweet=\"$EEFT - Euronet Worldwide +2.8% post Q3 results https://seekingalpha.com/news/3398956-euronet-worldwideplus-2_8-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3398956-euronet-worldwideplus-2_8-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:36 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398955\" data-ts=\"1539963156\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/UN\" target=\"_blank\">UN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398955-unilever-gains-alongside-p-and-g-beat-bryan-garnier-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Unilever gains alongside P&amp;G beat, Bryan Garnier upgrade</a></h4><ul>   <li>Unilever is up in NYSE trading (<a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a> <font color='green'>+3.4%</font>, <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a> <font color='green'>+3.4%</font>) -- in the wake of Procter &amp; Gamble's <a href=\"https://seekingalpha.com/news/3398841-p-and-g-gains-4_4-percent-premarket-fiscal-q1-eps-beats-reaffirms-year-guidance\" target=\"_blank\">beat this morning</a>, and alongside a boost from Bryan Garnier.</li>    <li>The firm's analyst Virginie Roumage upgraded its rating on Unilever's global depository receipts to Buy, from Neutral.</li>    <li>A few dozen other analysts are split nearly evenly between those two ratings on the stock.</li>    <li><a href='https://seekingalpha.com/symbol/UN' title='Unilever NV'>UN</a> is <font color='red'>down 14.2%</font> over the past 12 months, while <a href='https://seekingalpha.com/symbol/UL' title='Unilever Plc'>UL</a> is <font color='red'>off 12.9%</font> over that span.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398955\" data-linked=\"Unilever gains alongside P&amp;G beat, Bryan Garnier upgrade\" data-tweet=\"$UN $UN $UL - Unilever gains alongside P&amp;G beat, Bryan Garnier upgrade https://seekingalpha.com/news/3398955-unilever-gains-alongside-p-and-g-beat-bryan-garnier-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3398955-unilever-gains-alongside-p-and-g-beat-bryan-garnier-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:32 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398953\" data-ts=\"1539962478\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DOCU\" target=\"_blank\">DOCU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398953-docusign-down-on-wedbush-neutral-start-upcoming-lock-up-expiration\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">DocuSign down on Wedbush Neutral start, upcoming lock-up expiration</a></h4><ul><li>        Wedbush initiates DocuSign (NASDAQ:<a href='https://seekingalpha.com/symbol/DOCU' title='DocuSign, Inc.'>DOCU</a>) at Neutral with a $45 price target.</li><li>               The firm says DocuSign &ldquo;has done an impressive job of building out the $25B+ TAM&rdquo; around its e-signature solution and has made itself the &ldquo;go-to-vendor among enterprises of all shapes and sizes.&rdquo;&nbsp;</li><li>               Wedbush thinks DOCU could grow billings/revenue that &ldquo;handily exceed&rdquo; consensus over the next few years. But DOCU will have an uphill climb near-term with a new head of sales, increasing competition from Adobe and other smaller vendors, and significant investments needed to drive customer growth.&nbsp;</li><li>               Upcoming catalysts: The post-IPO lock-up period expires on October 24. Earnings expected in mid-December.&nbsp;</li><li>               Source: Research note.&nbsp;</li><li>               DocuSign shares are&nbsp;<font color='red'>down 5.5%</font>&nbsp;to $43.72.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3398953\" data-linked=\"DocuSign down on Wedbush Neutral start, upcoming lock-up expiration\" data-tweet=\"$DOCU - DocuSign down on Wedbush Neutral start, upcoming lock-up expiration https://seekingalpha.com/news/3398953-docusign-down-on-wedbush-neutral-start-upcoming-lock-up-expiration?source=tweet\" data-url=\"https://seekingalpha.com/news/3398953-docusign-down-on-wedbush-neutral-start-upcoming-lock-up-expiration\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:21 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398952\" data-ts=\"1539962358\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ACU\" target=\"_blank\">ACU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398952-acme-united-down-7-post-q3-earnings-miss\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Acme United down 7% post Q3 earnings miss</a></h4><ul><li>Acme United (<a href='https://seekingalpha.com/symbol/ACU' title='Acme United Corporation'>ACU</a> <font color='red'>-7.5%</font>) reported Q3 net sales of $34.7M an increase of 2.8% Y/Y, reflecting the success of Westcott back-to-school scissors, Camillus knives, and first aid products.</li><li>U.S.&nbsp;net sales increased by 3%&nbsp;Y/Y; Europe net sales increased by 2% Y/Y in&nbsp;U.S.&nbsp;dollars and 3% Y/Y in local currency; and Canada increased 2% Y/Y in&nbsp;U.S.&nbsp;dollars and 6% Y/Y in local currency.</li><li>Q3 Gross margin 35.8%&nbsp;<font color='red'>down by 35 bps</font>&nbsp;and operating margin 3.9%&nbsp;<font color='red'>down by 188 bps</font>.</li><li>SG&amp;A expenses increased by 8% Y/Y to $11.08M.</li><li>Company&rsquo;s bank debt less cash on September 30, 2018 was $46.5M compared to $38.9M a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398885-acme-united-misses-0_22-misses-revenue\" target=\"_blank\">Acme United misses by $0.22, misses on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398952\" data-linked=\"Acme United down 7% post Q3 earnings miss\" data-tweet=\"$ACU - Acme United down 7% post Q3 earnings miss https://seekingalpha.com/news/3398952-acme-united-down-7-post-q3-earnings-miss?source=tweet\" data-url=\"https://seekingalpha.com/news/3398952-acme-united-down-7-post-q3-earnings-miss\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:19 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398951\" data-ts=\"1539962227\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/TMP\" target=\"_blank\">TMP</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398951-tompkins-dips-2-after-q3-results-disappoint\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Tompkins dips 2% after Q3 results disappoint</a></h4><ul><li>Tompkins Financial (NYSEMKT:<a href='https://seekingalpha.com/symbol/TMP' title='Tompkins Financial Corporation'>TMP</a>)&nbsp;<font color='red'>slips 2.0%</font>&nbsp;after <a href=\"https://seekingalpha.com/pr/17306217-tompkins-financial-corporation-reports-record-year-date-third-quarter-earnings\" target=\"_blank\">Q3 adjusted EPS</a> of $1.38 failed to meet consensus estimate of $1.40; compares with $1.39 in Q2 and $1.14 a year ago.</li><li>\"The current interest rate environment is challenging as we, along with most in our industry, have seen narrowing of our net interest margin,\" says President and CEO Stephen S. Romaine.</li><li>Q3 net interest income of $53.2M increases from $51.0M a year ago.</li><li>Q3 net interest margin of 3.35% compares with 3.36% in Q2 and 3.40% a year ago.</li><li>Q3 noninterest income rises to $7.9M from $7.7M a year ago.</li><li>Total loans of $4.8B at Sept. 30, 2018, up 7.0% from a year ago and up 2.9% from Dec. 31, 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398895-tompkins-financial-misses-0_04-misses-revenue\" target=\"_blank\">Tompkins Financial misses by $0.04, misses on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398951\" data-linked=\"Tompkins dips 2% after Q3 results disappoint\" data-tweet=\"$TMP - Tompkins dips 2% after Q3 results disappoint https://seekingalpha.com/news/3398951-tompkins-dips-2-after-q3-results-disappoint?source=tweet\" data-url=\"https://seekingalpha.com/news/3398951-tompkins-dips-2-after-q3-results-disappoint\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:17 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398949\" data-ts=\"1539961864\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MAN\" target=\"_blank\">MAN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398949-manpower-down-4-post-mixed-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Manpower down 4% post mixed Q3 results</a></h4><ul>     <li>Manpower (<a href='https://seekingalpha.com/symbol/MAN' title='ManpowerGroup Inc.'>MAN</a> <font color='red'>-4.7%</font>) <a href=\"https://seekingalpha.com/pr/17306052-manpowergroup-reports-3rd-quarter-2018-results\" target=\"_blank\">reports</a> revenue rose 1% on a constant currency basis in Q3.</li>     <li>Revenue from services: Americas: $1.04B (-2.0%); Southern Europe: $2.33B (+0.6%); Northern Europe: $1.29B (-5.9%); APME: $713M (+7.2%); Right Management: $47M (-8.9%).</li>     <li>Jonas Prising, ManpowerGroup Chairman &amp; CEO: \"We are anticipating the fourth quarter of 2018 diluted net earnings per share to be in the range of $2.15 to $2.23, which includes an estimated unfavorable currency impact of 5 cents. This includes an estimated one-time negative impact of 27 cents related to reduced gross profit in France\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398840-manpower-beats-0_02-misses-revenue\" target=\"_blank\">Manpower beats by $0.02, misses on revenue</a> (Oct. 19)</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398949\" data-linked=\"Manpower down 4% post mixed Q3 results\" data-tweet=\"$MAN - Manpower down 4% post mixed Q3 results https://seekingalpha.com/news/3398949-manpower-down-4-post-mixed-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3398949-manpower-down-4-post-mixed-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398947\" data-ts=\"1539961471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NETE\" target=\"_blank\">NETE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398947-netelement-gains-on-director-picking-up-shares\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">NetElement gains on director picking up more shares</a></h4><ul><li>        Net Element (NASDAQ:<a href='https://seekingalpha.com/symbol/NETE' title='Net Element International, Inc.'>NETE</a>)&nbsp;<font color='green'>gains 8.4%</font>&nbsp;to $4.10 after yesterday&rsquo;s <a href=\"https://seekingalpha.com/filing/4204505\" target=\"_blank\">Form 4 filing</a> showing that director Rakishev Kenges acquired 701 shares and bumped beneficial ownership up to 198,676 shares.</li><li>        The acquisition didn&rsquo;t carry a cost.&nbsp;                 </li></ul><div class=\"tiny-share-widget\" data-id=\"3398947\" data-linked=\"NetElement gains on director picking up more shares\" data-tweet=\"$NETE - NetElement gains on director picking up more shares https://seekingalpha.com/news/3398947-netelement-gains-on-director-picking-up-shares?source=tweet\" data-url=\"https://seekingalpha.com/news/3398947-netelement-gains-on-director-picking-up-shares\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398946\" data-ts=\"1539961253\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XOMA\" target=\"_blank\">XOMA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398946-bouncing-xoma-leads-mid-morning-healthcare-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bouncing XOMA leads mid-morning healthcare gainers</a></h4><ul><li><b>Gainers:</b> <a href='https://seekingalpha.com/symbol/XOMA' title='XOMA Corporation'>XOMA</a> <font color='green'>+18%</font>. <a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/VTVT' title='vTv Therapeutics'>VTVT</a> <font color='green'>+16%</font>. <a href='https://seekingalpha.com/symbol/NTGN' title='Neon Therapeutics'>NTGN</a> <font color='green'>+14%</font>. <a href='https://seekingalpha.com/symbol/RMED' title='Ra Medical Systems'>RMED</a> <font color='green'>+12%</font>.</li><li><b>Losers:</b> <a href='https://seekingalpha.com/symbol/MACK' title='Merrimack Pharmaceuticals'>MACK</a> <font color='red'>-33%</font>. <a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color='red'>-24%</font>. <a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-16%</font>. <a href='https://seekingalpha.com/symbol/EYPT' title='EyePoint Pharmaceuticals, Inc.'>EYPT</a> <font color='red'>-14%</font>.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398946\" data-linked=\"Bouncing XOMA leads mid-morning healthcare gainers\" data-tweet=\"$XOMA $XOMA $AVXL - Bouncing XOMA leads mid-morning healthcare gainers https://seekingalpha.com/news/3398946-bouncing-xoma-leads-mid-morning-healthcare-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398946-bouncing-xoma-leads-mid-morning-healthcare-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 11:00 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398944\" data-ts=\"1539960924\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/RENN\" target=\"_blank\">RENN</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398944-renrenplus-7_8-on-stock-incentive-filing\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Renren +7.8% on stock incentive filing</a></h4><ul><li>        Renren (NYSE:<a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a>)&nbsp;<font color='green'>gains 7.8%</font>&nbsp;to $1.79 after <a href=\"https://seekingalpha.com/filing/4205334\" target=\"_blank\">filing</a> a 2018 share incentive plan.</li><li>               The amounts to be registered include about 86.9M Class A shares at a maximum $0.10/share or $8.69M with a $1.1K registration fee and 20.2M shares at the same price for $2.02M with a $224.28 fee.&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3398944\" data-linked=\"Renren +7.8% on stock incentive filing\" data-tweet=\"$RENN - Renren +7.8% on stock incentive filing https://seekingalpha.com/news/3398944-renrenplus-7_8-on-stock-incentive-filing?source=tweet\" data-url=\"https://seekingalpha.com/news/3398944-renrenplus-7_8-on-stock-incentive-filing\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:55 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398942\" data-ts=\"1539960583\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/GNTX\" target=\"_blank\">GNTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398942-gentex-updates-fy2018-guidance-shares-up-5_3\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Gentex updates FY2018 guidance, shares up 5.3%</a></h4><ul><li>Gentex (<a href='https://seekingalpha.com/symbol/GNTX' title='Gentex Corporation'>GNTX</a> <font color='green'>+5.3%</font>)&nbsp;reports Automotive net sales rose 5% to $449.2M in&nbsp;<a href=\"https://seekingalpha.com/pr/17306103-gentex-reports-third-quarter-2018-financial-results\" target=\"_blank\">Q3</a>,&nbsp;aided by an 6%&nbsp;increase in auto-dimming mirror unit shipments sequentially.</li><li>Total auto-dimming mirror units +6% Y/Y to 10,229.</li><li>Gross margin&nbsp;<font color='red'>declined 160 bps</font>&nbsp;to 37.6% &amp; Operating margin&nbsp;<font color='red'>declined 175 bps</font>&nbsp;to 27.7%.</li><li>The company repurchased ~7.5M&nbsp;shares during the quarter at an average price of $22.98 per share.</li><li><b>FY2018 Guidance</b>: Net sales: $1.85-1.87B; Gross margin rate: 37.5%-38.0%; Operating expense: $180-185M; Tax rate: 15%-18%; Capex: $95-105M; D&amp;A: $105-110M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398849-gentex-eps-line-misses-revenue\" target=\"_blank\">Gentex EPS in-line, misses on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398942\" data-linked=\"Gentex updates FY2018 guidance, shares up 5.3%\" data-tweet=\"$GNTX - Gentex updates FY2018 guidance, shares up 5.3% https://seekingalpha.com/news/3398942-gentex-updates-fy2018-guidance-shares-up-5_3?source=tweet\" data-url=\"https://seekingalpha.com/news/3398942-gentex-updates-fy2018-guidance-shares-up-5_3\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:49 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398941\" data-ts=\"1539960446\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NSRGY\" target=\"_blank\">NSRGY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398941-bloomberg-j-and-j-kkr-be-buyers-for-nestles-skin-health-unit\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bloomberg: J&amp;J, KKR could be buyers for Nestle&#39;s skin health unit</a></h4><ul><li>Nestle (<a href='https://seekingalpha.com/symbol/NSRGY' title='Nestle S.A. ADR'>OTCPK:NSRGY</a> <font color='green'>+3.4%</font>) is working with advisers on a <a href=\"https://www.bloomberg.com/news/articles/2018-10-19/nestle-is-said-to-work-with-advisers-to-review-skin-health-unit\" target=\"_blank\">potential sale of its skin care division</a> which could fetch $8B-$10B,  as it moves ahead with plans to narrow its sprawling  business interests, Bloomberg reports.</li><li>The division may attract bids from personal care companies such as  Johnson &amp; Johnson (<a href='https://seekingalpha.com/symbol/JNJ' title='Johnson & Johnson'>JNJ</a> <font color='green'>+0.1%</font>) and P-E firms including <a href='https://seekingalpha.com/symbol/KKR' title='KKR'>KKR</a> and Apax Partners, according to the report.</li><li>Nestle is weighing a sale of the operations as a whole or in parts  and may consider a spinoff, although that option reportedly is less likely; deliberations are said to be at an early stage.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398941\" data-linked=\"Bloomberg: J&amp;J, KKR could be buyers for Nestle&#39;s skin health unit\" data-tweet=\"$NSRGY $NSRGY $JNJ - Bloomberg: J&amp;J, KKR could be buyers for Nestle&#39;s skin health unit https://seekingalpha.com/news/3398941-bloomberg-j-and-j-kkr-be-buyers-for-nestles-skin-health-unit?source=tweet\" data-url=\"https://seekingalpha.com/news/3398941-bloomberg-j-and-j-kkr-be-buyers-for-nestles-skin-health-unit\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:47 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398940\" data-ts=\"1539960205\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OFG\" target=\"_blank\">OFG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398940-ofg-bancorp-jumps-11-puerto-rico-recovers-from-last-years-storms\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">OFG Bancorp jumps 11% as Puerto Rico recovers from last year&#39;s storms</a></h4><ul><li>OFG Bancorp (NYSE:<a href='https://seekingalpha.com/symbol/OFG' title='OFG Bancorp'>OFG</a>)<font color='green'> surges 11%&nbsp;</font>after <a href=\"https://seekingalpha.com/pr/17306056-ofg-bancorp-reports-3q18-results\" target=\"_blank\">Q3 results </a>easily beat consensus, buoyed by Puerto Rico's rebound after hurricanes battered the island in September of last year.</li><li>Q3 EPS of 42 cents surpassed consensus estimate of 36 cents; that compares with 35 cents in Q2 and break-even in the year-ago quarter.</li><li>Q3 net interest income increased to $82.3M from $77.6M in Q2 and $80.5M in Q3 2017; net interest margin of 5.38% vs. 5.24% in Q2 and 5.64% in the year-ago quarter.</li><li>Q3 core net non-interest income of $18.4M was unchanged from Q2, and up from $17.2M a year ago.</li><li>Q3 net charge-off rate was 1.39% vs. 1.81% in Q2 and 1.54% in Q3 2017.</li><li>Book value per common share of $18.27 vs. $18.01 in Q2 and $17.56 a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398843-ofg-bancorp-beats-0_06-beats-revenue\" target=\"_blank\">OFG Bancorp beats by $0.06, beats on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398940\" data-linked=\"OFG Bancorp jumps 11% as Puerto Rico recovers from last year&#39;s storms\" data-tweet=\"$OFG - OFG Bancorp jumps 11% as Puerto Rico recovers from last year&#39;s storms https://seekingalpha.com/news/3398940-ofg-bancorp-jumps-11-puerto-rico-recovers-from-last-years-storms?source=tweet\" data-url=\"https://seekingalpha.com/news/3398940-ofg-bancorp-jumps-11-puerto-rico-recovers-from-last-years-storms\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:43 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398939\" data-ts=\"1539959987\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/KSU\" target=\"_blank\">KSU</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398939-kansas-city-southernplus-3-after-in-line-earnings-higher-carload-volume\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Kansas City Southern +3% after in\u2010line earnings, higher carload volume</a></h4><ul>     <li>Kansas City Southern (<a href='https://seekingalpha.com/symbol/KSU' title='Kansas City Southern'>KSU</a> <font color='green'>+3.2%</font>) sports a solid gain after reporting in-line <a href=\"https://seekingalpha.com/news/3398851-kansas-city-southern-eps-line-misses-revenue\" target=\"_blank\">Q3 earnings</a> that rose 35% Y/Y, with <a href=\"https://www.marketwatch.com/story/kansas-city-southern-profit-up-on-higher-carloads-2018-10-19\" target=\"_blank\">increases in carload volume</a> and product shipments in several of its commodity segments.</li>     <li>KSU says Q3 revenues rose 6% to $699M, aided by a 17% jump in revenue to $160M from the chemicals and petroleum segment, an 8% gain in intermodal revenue to $100M and an 8% increase from the automotive unit to $66M; revenue in industrial and consumer products, and in agriculture and minerals was little changed, while energy fell 2%.</li><li>KSU says it faced a \"challenging third quarter, as network congestion in northern Mexico led to a difficult operating environment. However, we have taken steps that we are confident will restore our service levels.\"</li></ul><div class=\"tiny-share-widget\" data-id=\"3398939\" data-linked=\"Kansas City Southern +3% after in\u2010line earnings, higher carload volume\" data-tweet=\"$KSU - Kansas City Southern +3% after in\u2010line earnings, higher carload volume https://seekingalpha.com/news/3398939-kansas-city-southernplus-3-after-in-line-earnings-higher-carload-volume?source=tweet\" data-url=\"https://seekingalpha.com/news/3398939-kansas-city-southernplus-3-after-in-line-earnings-higher-carload-volume\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:39 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398938\" data-ts=\"1539959879\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCTY\" target=\"_blank\">NCTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398938-the9-vaults-197-consultant-takes-7_4-stake\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">The9 vaults 197% as consultant takes 7.4% stake</a></h4><ul>   <li>Mobile game maker The9 (NASDAQ:<a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a>) has edged close to tripling up on the day, <font color='green'>up 197%</font>, after disclosing that company consultant Jie Qin has <a href=\"https://seekingalpha.com/filing/4205279\" target=\"_blank\">taken a 7.4% stake</a> in the company.</li>    <li>A filing shows Jie Qin acquired sole voting power in 9M shares.</li>    <li>\"Mr. Qin is a consultant of the Issuer. He has more than 20 years of experience in internet and game industries and has provided consulting services with respect to the internet and game industries to the Issuer since 2005,\" the company says in the filing.</li>    <li>Shares had <a href=\"https://seekingalpha.com/news/3398752-game-maker-the9-67-percent-hours\" target=\"_blank\">begun moving postmarket</a> last night.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398938\" data-linked=\"The9 vaults 197% as consultant takes 7.4% stake\" data-tweet=\"$NCTY - The9 vaults 197% as consultant takes 7.4% stake https://seekingalpha.com/news/3398938-the9-vaults-197-consultant-takes-7_4-stake?source=tweet\" data-url=\"https://seekingalpha.com/news/3398938-the9-vaults-197-consultant-takes-7_4-stake\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398937\" data-ts=\"1539959588\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PLAG\" target=\"_blank\">PLAG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398937-planet-green-up-331-shares-halted-pending-news\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Planet Green up 331%; shares halted pending news</a></h4><ul><li>Shanghai-based Planet Green (NYSEMKT:<a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a>) has nearly quadrupled in early morning action, with shares currently halted pending news.</li><li>The company earlier this week <a href=\"https://seekingalpha.com/pr/17303194-planet-green-holdings-corp-closes-previously-announced-financing-transaction\" target=\"_blank\">raised $10M</a> from management in a private placement.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398937\" data-linked=\"Planet Green up 331%; shares halted pending news\" data-tweet=\"$PLAG - Planet Green up 331%; shares halted pending news https://seekingalpha.com/news/3398937-planet-green-up-331-shares-halted-pending-news?source=tweet\" data-url=\"https://seekingalpha.com/news/3398937-planet-green-up-331-shares-halted-pending-news\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:33 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>8&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398934\" data-ts=\"1539959476\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/MINI\" target=\"_blank\">MINI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398934-mobile-mini-down-3-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Mobile Mini down 3% post Q3 results</a></h4><ul><li>Mobile Mini (<a href='https://seekingalpha.com/symbol/MINI' title='Mobile Mini, Inc.'>MINI</a> <font color='red'>-3%</font>) reported Q3 revenue increase of 9.6% Y/Y to $149.71M. Segment revenue: Solution storage $120.37M (+7.8% Y/Y) and Tank &amp; pump solution $29.33M (+17.3% Y/Y).</li><li>Rental revenue growth: Tank &amp; Pump Solutions $28.28M (+21.9% Y/Y) and Storage Solutions $112.64M (+7.8% Y/Y).</li><li>Q3 Adj. operating margin&nbsp;<font color='green'>improved by 445 bps&nbsp;</font>to 24.7% and Adj. EBITDA margin i<font color='green'>mproved by 370 bps</font>&nbsp;to 37%.</li><li>Storage Solutions - utilization based on number of units expanded 610 bps to 77.9% and Tank &amp; Pump Solutions - utilization based on OEC expanded 560 bps to 72.2%.</li><li>Company reported net cash from operating activities of $46.3M and free cash flow of $17.5M.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398801-mobile-mini-beats-0_01-beats-revenue\" target=\"_blank\">Mobile Mini beats by $0.01, beats on revenue</a> (Oct. 19)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398798-mobile-mini-declares-0_25-dividend\" target=\"_blank\">Mobile Mini declares $0.25 dividend</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398934\" data-linked=\"Mobile Mini down 3% post Q3 results\" data-tweet=\"$MINI - Mobile Mini down 3% post Q3 results https://seekingalpha.com/news/3398934-mobile-mini-down-3-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3398934-mobile-mini-down-3-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:31 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398935\" data-ts=\"1539959405\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/INCY\" target=\"_blank\">INCY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398935-incytes-capmatinib-shows-positive-action-in-mid-stage-lung-cancer-study-shares-ahead-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Incyte&#39;s capmatinib shows positive action in mid-stage lung cancer study; shares ahead 2%</a></h4><ul><li>Incyte (<a href='https://seekingalpha.com/symbol/INCY' title='Incyte Corporation'>INCY</a> <font color='green'>+2.4%</font>) is up on below-average volume following its <a href=\"https://seekingalpha.com/pr/17306313-phase-2-geometry-monominus-1-trial-investigational-medicine-capmatinib-shows-positive-results\" target=\"_blank\">announcement </a>of positive results from a Phase 2 clinical trial, GEOMETRY mono-1, evaluating MET inhibitor capmatinib in 94 adult patients with advanced non-small cell lung cancer &#40;NSCLC&#41; with MET exon-14-skipping mutations. The data are being presented at ESMO in Munich.</li><li>The overall response rates (ORRs) in treatment-naive and treatment-experienced patients were 72.0% and 39.1%, respectively.</li><li>About 3 - 4% of NSCLC patients harbor MET mutations.</li><li>Licensee Novartis (<a href='https://seekingalpha.com/symbol/NVS' title='Novartis AG'>NVS</a> <font color='green'>+1.4%</font>) expects to file a U.S. marketing application for the indication in 2019.</li><li>#ESMO</li></ul><div class=\"tiny-share-widget\" data-id=\"3398935\" data-linked=\"Incyte&#39;s capmatinib shows positive action in mid-stage lung cancer study; shares ahead 2%\" data-tweet=\"$INCY $INCY $NVS - Incyte&#39;s capmatinib shows positive action in mid-stage lung cancer study; shares ahead 2% https://seekingalpha.com/news/3398935-incytes-capmatinib-shows-positive-action-in-mid-stage-lung-cancer-study-shares-ahead-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3398935-incytes-capmatinib-shows-positive-action-in-mid-stage-lung-cancer-study-shares-ahead-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:30 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398924\" data-ts=\"1539958541\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IDRA\" target=\"_blank\">IDRA</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398924-idera-presents-new-data-on-tilsotolimod-investors-unmoved-shares-down-8\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Idera presents new data on tilsotolimod; investors unmoved, shares down 8%</a></h4><ul><li>Idera Pharmaceuticals (<a href='https://seekingalpha.com/symbol/IDRA' title='Idera Pharmaceuticals, Inc.'>IDRA</a> <font color='red'>-8.2%</font>) is down on light volume in early trade following its <a href=\"https://seekingalpha.com/pr/17305969-idera-pharmaceuticals-presents-data-illuminateminus-204-trial-combination-tilsotolimod\" target=\"_blank\">announcement </a>of new data from its <a href=\"https://clinicaltrials.gov/ct2/show/NCT02644967?titles=illuminate-204&amp;lead=idera&amp;rank=1\" target=\"_blank\">ILLUMINATE-204</a> study evaluating tilsotolimod plus BMY's Yervoy (ipilimumab) in patients with advanced melanoma who failed to respond adequately to Merck's Keytruda (pembrolizumab). The results are being presented at ESMO in Munich.</li><li>The overall response rate &#40;ORR&#41; was 39% (n=8/21 which is 38%) with seven of the eight experiencing tumor shrinkage in both injected and uninjected tumors. Four additional patients showed tumor shrinkage in uninjected lesions but they did not meet RECIST response criteria.</li><li>#ESMO</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361391-idera-pharma-11-percent-despite-encouraging-tilsotolimod-data-melanoma\" target=\"_blank\">Idera Pharma down 11% despite encouraging tilsotolimod data in melanoma</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398924\" data-linked=\"Idera presents new data on tilsotolimod; investors unmoved, shares down 8%\" data-tweet=\"$IDRA - Idera presents new data on tilsotolimod; investors unmoved, shares down 8% https://seekingalpha.com/news/3398924-idera-presents-new-data-on-tilsotolimod-investors-unmoved-shares-down-8?source=tweet\" data-url=\"https://seekingalpha.com/news/3398924-idera-presents-new-data-on-tilsotolimod-investors-unmoved-shares-down-8\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:15 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398923\" data-ts=\"1539958312\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DELL\" target=\"_blank\">DELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398923-dell-plans-dec-11-vote-on-tracking-stock-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dell plans Dec. 11 vote on tracking stock buyback</a></h4><ul><li>        Dell (DVMT) will ask tracking stockholders to vote on the $21.7B buyback offer on December 11, according to <a href=\"https://www.reuters.com/article/us-dell-trackingstock/dell-to-take-21-7-billion-tracking-stock-offer-to-december-vote-sources-idUSKCN1MT1Y9\" target=\"_blank\">Reuters sources</a>.</li><li>               Investor Carl Icahn, who has an 8.3% stake in the stock that tracks VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>), has publicly pushed back at the plan, saying it would unfairly give $11B in value to Dell&rsquo;s controlling shareholders.&nbsp;</li><li>               The tracking stock came to life in 2016 because Dell needed more money for its $67B purchase of data storage company EMC, which held a majority stake in VMware.&nbsp;</li><li>               If the vote passes, Dell could become public again without an IPO. But the company has admitted a traditional IPO as a backup plan.&nbsp;</li><li>               Dell shares are&nbsp;<font color='green'>up 0.6%</font>&nbsp;to $94.99.&nbsp;</li><li>               VMware shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $147.10.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394720-dell-confirms-ipo-talks-back-plan\" target=\"_blank\">Dell confirms IPO talks as back-up plan</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395419-dell-will-list-nyse-tracking-stock-buyout-succeeds\" target=\"_blank\">Dell will list on NYSE if tracking stock buyout succeeds</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395480-cnbcs-faber-dell-might-lack-votes-tracking-stock-buyout\" target=\"_blank\">CNBC's Faber: Dell might lack votes for tracking stock buyout</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397201-icahn-discloses-8-percent-stake-dell-tracker-will-oppose-merger\" target=\"_blank\">Icahn discloses 8% stake in Dell tracker, will oppose merger</a> (Oct. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397760-dell-sticks-tracking-stock-plan-despite-icahn-disapproval\" target=\"_blank\">Dell sticks with tracking stock plan despite Icahn disapproval</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398923\" data-linked=\"Dell plans Dec. 11 vote on tracking stock buyback\" data-tweet=\"$DELL $DELL $VMW - Dell plans Dec. 11 vote on tracking stock buyback https://seekingalpha.com/news/3398923-dell-plans-dec-11-vote-on-tracking-stock-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3398923-dell-plans-dec-11-vote-on-tracking-stock-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>9&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398922\" data-ts=\"1539958292\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DELL\" target=\"_blank\">DELL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398922-dell-plans-dec-11-vote-on-tracking-stock-buyback\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Dell plans Dec. 11 vote on tracking stock buyback</a></h4><ul><li>        Dell (DVMT) will ask tracking stockholders to vote on the $21.7B buyback offer on December 11, according to <a href=\"https://www.reuters.com/article/us-dell-trackingstock/dell-to-take-21-7-billion-tracking-stock-offer-to-december-vote-sources-idUSKCN1MT1Y9\" target=\"_blank\">Reuters sources</a>.</li><li>               Investor Carl Icahn, who has an 8.3% stake in the stock that tracks VMware (NYSE:<a href='https://seekingalpha.com/symbol/VMW' title='VMware, Inc.'>VMW</a>), has publicly pushed back at the plan, saying it would unfairly give $11B in value to Dell&rsquo;s controlling shareholders.&nbsp;</li><li>               The tracking stock came to life in 2016 because Dell needed more money for its $67B purchase of data storage company EMC, which held a majority stake in VMware.&nbsp;</li><li>               If the vote passes, Dell could become public again without an IPO. But the company has admitted a traditional IPO as a backup plan.&nbsp;</li><li>               Dell shares are&nbsp;<font color='green'>up 0.6%</font>&nbsp;to $94.99.&nbsp;</li><li>               VMware shares are&nbsp;<font color='green'>up 1%</font>&nbsp;to $147.10.&nbsp;&nbsp;</li><li>Previously: <a href=\"https://seekingalpha.com/news/3394720-dell-confirms-ipo-talks-back-plan\" target=\"_blank\">Dell confirms IPO talks as back-up plan</a> (Oct. 3)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395419-dell-will-list-nyse-tracking-stock-buyout-succeeds\" target=\"_blank\">Dell will list on NYSE if tracking stock buyout succeeds</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3395480-cnbcs-faber-dell-might-lack-votes-tracking-stock-buyout\" target=\"_blank\">CNBC's Faber: Dell might lack votes for tracking stock buyout</a> (Oct. 5)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397201-icahn-discloses-8-percent-stake-dell-tracker-will-oppose-merger\" target=\"_blank\">Icahn discloses 8% stake in Dell tracker, will oppose merger</a> (Oct. 15)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3397760-dell-sticks-tracking-stock-plan-despite-icahn-disapproval\" target=\"_blank\">Dell sticks with tracking stock plan despite Icahn disapproval</a> (Oct. 16)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398922\" data-linked=\"Dell plans Dec. 11 vote on tracking stock buyback\" data-tweet=\"$DELL $DELL $VMW - Dell plans Dec. 11 vote on tracking stock buyback https://seekingalpha.com/news/3398922-dell-plans-dec-11-vote-on-tracking-stock-buyback?source=tweet\" data-url=\"https://seekingalpha.com/news/3398922-dell-plans-dec-11-vote-on-tracking-stock-buyback\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span> 10:11 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398914\" data-ts=\"1539957260\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OZK\" target=\"_blank\">OZK</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398914-bank-ozk-plunges-23-q3-shows-chink-in-portfolios-imperviousness\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bank OZK plunges 23% as Q3 shows chink in portfolio&#39;s `imperviousness&#39;</a></h4><ul><li>Bank OZK (NASDAQ:<a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a>)<font color='red'> sinks 23%</font>&nbsp;after Q3 earnings fall short of consensus, dinged by rebranding costs and two big credit charge-offs.</li><li>The stock's decline comes from Q3 showing OZK portfolio's \"imperviousness\" is breached, combined with slower growth and lower NIM, says Raymond James analyst Michael Rose.</li><li>Bank OZK's woes are \"very company specific\" and aren't a reflection of the overall credit quality, he says. \"Credit across the industry is still solid.\"</li><li>Even for Bank OZK, \"the issues are small and the business isn't broken,\" he comments.</li><li>Source: Bloomberg First Word.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398732-bank-ozk-dives-20-percent-q3-hobbled-rebranding-costs-charge-offs\" target=\"_blank\">Bank OZK dives 20% as Q3 hobbled with rebranding costs, charge-offs</a> (Oct. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398914\" data-linked=\"Bank OZK plunges 23% as Q3 shows chink in portfolio&#39;s `imperviousness&#39;\" data-tweet=\"$OZK - Bank OZK plunges 23% as Q3 shows chink in portfolio&#39;s `imperviousness&#39; https://seekingalpha.com/news/3398914-bank-ozk-plunges-23-q3-shows-chink-in-portfolios-imperviousness?source=tweet\" data-url=\"https://seekingalpha.com/news/3398914-bank-ozk-plunges-23-q3-shows-chink-in-portfolios-imperviousness\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:54 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>78&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398910\" data-ts=\"1539957023\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BIIB\" target=\"_blank\">BIIB</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398910-bernstein-softens-view-on-biogen-fully-valued-due-lack-of-catalysts-shares-down-2\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Bernstein softens view on Biogen, fully valued due lack of catalysts; shares down 2%</a></h4><ul><li>Bernstein's Ronny Gal has trimmed his view on Biogen (<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a> <font color='red'>-1.7%</font>) to Market Perform with a $314 (5% downside risk) fair value target citing a dearth of catalysts after data on Alzheimer's candidate aducanumab are presented at a Barcelona conference next week.</li><li>He also believes that the company may cut earnings guidance due to competition for Spinraza and its MS franchise.</li><li>Source: Bloomberg</li></ul><div class=\"tiny-share-widget\" data-id=\"3398910\" data-linked=\"Bernstein softens view on Biogen, fully valued due lack of catalysts; shares down 2%\" data-tweet=\"$BIIB - Bernstein softens view on Biogen, fully valued due lack of catalysts; shares down 2% https://seekingalpha.com/news/3398910-bernstein-softens-view-on-biogen-fully-valued-due-lack-of-catalysts-shares-down-2?source=tweet\" data-url=\"https://seekingalpha.com/news/3398910-bernstein-softens-view-on-biogen-fully-valued-due-lack-of-catalysts-shares-down-2\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:50 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>5&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398909\" data-ts=\"1539956718\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/EXPO\" target=\"_blank\">EXPO</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398909-exponentplus-3_5-post-q3-results\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Exponent +3.5% post Q3 results</a></h4><ul><li>Exponent (<a href='https://seekingalpha.com/symbol/EXPO' title='Exponent, Inc.'>EXPO</a> <font color='green'>+3.5%</font>) <u><a href=\"https://seekingalpha.com/pr/17305675-exponent-reports-third-quarter-fiscal-year-2018-financial-results\" target=\"_blank\">reports Q3</a></u>&nbsp;revenue growth of 8.8% Y/Y to $95.3M.</li><li>Revenues before reimbursements were $88.7M (+8% Y/Y) &amp; Reimbursements of $6.6M (+26.9% Y/Y).</li><li>Operating margin&nbsp;<font color='red'>declined 41 bps</font>&nbsp;to 21.6% &amp; EBIDTA margin&nbsp;<font color='red'>declined 46 bps</font>&nbsp;to 26%.</li><li>The company declared a quarterly cash dividend of $0.13/share.</li><li><strong>Outlook 2018:</strong> We expect revenues before reimbursements to grow in the high-single digits and EBITDA<sup>&nbsp;</sup>margin to increase by ~50 bps Y/Y; consolidated income tax rate ~22%-23% for 2018.</li><li>&ldquo;Exponent&rsquo;s unique market position, adaptable business model and diverse clientele position us well for long-term growth.&rdquo; said Dr. Catherine Corrigan, President and CEO.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398658-exponent-misses-0_02-beats-revenue\" target=\"_blank\">Exponent misses by $0.02, beats on revenue</a> (Oct. 18)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398645-exponent-declares-0_13-dividend\" target=\"_blank\">Exponent declares $0.13 dividend</a> (Oct. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398909\" data-linked=\"Exponent +3.5% post Q3 results\" data-tweet=\"$EXPO - Exponent +3.5% post Q3 results https://seekingalpha.com/news/3398909-exponentplus-3_5-post-q3-results?source=tweet\" data-url=\"https://seekingalpha.com/news/3398909-exponentplus-3_5-post-q3-results\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:45 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398907\" data-ts=\"1539956305\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CFG\" target=\"_blank\">CFG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398907-citizens-financial-climbs-1_8-after-q3-earnings-beat\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Citizens Financial climbs 1.8% after Q3 earnings beat</a></h4><ul><li>Citizens Financial Group (NYSE:<a href='https://seekingalpha.com/symbol/CFG' title='Citizens Financial Group'>CFG</a>)&nbsp;<font color='green'>gains 1.8%&nbsp;</font>in early trading after <a href=\"https://seekingalpha.com/pr/17305987-citizens-financial-group-inc-reports-third-quarter-net-income-443-million-diluted-eps-0_91-34\" target=\"_blank\">Q3 underlying EPS</a> of 93 cents surpasses consensus estimate by 4 cents.</li><li>Q3 net interest income of $1.15B rose 2% Q/Q, fueled by higher loan yields, loan growth, and the benefit of day count; net interest margin of 3.19% improves by 1 basis point, as higher loans yields were partly offset by a 1 bp reduction tied to the FAMC acquisition.Year-ago NIM was 3.05%.</li><li>Q3 noninterest income of $416M rose 7% Q/Q, helped by the $24M impact of the FAMC acquisition, largely in mortgage banking fees as well as higher service charges and fees, and trust and investment services fees.</li><li>Total assets of $158.6B as of Sept. 30, 2018 rose 2% from Q2, reflecting a $1.3B increase in loans and leases and a $1.7B increased from the FAMC acquisition.</li><li>Q3 return on average common equity of 8.8% vs. 8.7% in Q2 and 6.9% in Q3 2017.</li><li>Q3 common equity tier 1 capital ratio of 10.8% vs. 11.2% in Q2 and 11.1% a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398800-citizens-financial-beats-0_04-revenue-line\" target=\"_blank\">Citizens Financial beats by $0.04,  revenue in-line</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398907\" data-linked=\"Citizens Financial climbs 1.8% after Q3 earnings beat\" data-tweet=\"$CFG - Citizens Financial climbs 1.8% after Q3 earnings beat https://seekingalpha.com/news/3398907-citizens-financial-climbs-1_8-after-q3-earnings-beat?source=tweet\" data-url=\"https://seekingalpha.com/news/3398907-citizens-financial-climbs-1_8-after-q3-earnings-beat\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:38 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398906\" data-ts=\"1539956279\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/BLRX\" target=\"_blank\">BLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398906-biolinerx-down-21-on-mid-stage-data-for-blminus-8040-in-pancreatic-cancer\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">BioLineRx down 21% on mid-stage data for BL-8040 in pancreatic cancer</a></h4><ul><li>BioLineRx (<a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a> <font color=\"red\">-21%</font>) is down out of the gate this morning as investors appear disappointed with <a href=\"https://seekingalpha.com/pr/17306030-biolinerx-presents-top-line-results-phase-2a-combat-keynoteminus-202-study-pancreatic-cancer\" target=\"_blank\">topline results</a> from a Phase 2a clinical trial evaluating lead candidate BL-8040 plus Merck's (<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a> <font color=\"red\">-0.1%</font>) Keytruda (pembrolizumab) in patients with metastatic pancreatic adenocarcinoma &#40;PDAC&#41;. The data are being presented at ESMO in Munich.</li><li>The study enrolled 37 patients who progressed after one or more lines of therapy. The disease control rate &#40;DCR&#41; (responders + stable cancer) was 34.5% (n=10/29) in evaluable participants, but there was only one partial responder. Median overall survival &#40;OS&#41; was 3.3 months. The six-month survival rate was 34.4%.</li><li>The triple combination arm (BL-8040/Keytruda/chemo) in a second-line setting will commence later this quarter with topline data expected in H2 2019.</li><li>#ESMO</li><li>Previously: <a href=\"https://seekingalpha.com/news/3235402-biolinerx-initiates-mid-stage-study-blminus-8040-keytruda-combo-pancreatic-cancer-shares-11\" target=\"_blank\">BioLineRx initiates mid-stage study of BL-8040/KEYTRUDA combo for pancreatic cancer; shares up 11% premarket</a> (Jan. 17, 2017)</li><li>Previously: <a href=\"https://seekingalpha.com/news/3375264-biolinerx-expands-immuno-oncology-collaboration-pancreatic-cancer\" target=\"_blank\">BioLineRx expands immuno-oncology collaboration in pancreatic cancer</a> (July 30)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398906\" data-linked=\"BioLineRx down 21% on mid-stage data for BL-8040 in pancreatic cancer\" data-tweet=\"$BLRX $BLRX $MRK - BioLineRx down 21% on mid-stage data for BL-8040 in pancreatic cancer https://seekingalpha.com/news/3398906-biolinerx-down-21-on-mid-stage-data-for-blminus-8040-in-pancreatic-cancer?source=tweet\" data-url=\"https://seekingalpha.com/news/3398906-biolinerx-down-21-on-mid-stage-data-for-blminus-8040-in-pancreatic-cancer\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:37 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>17&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398899\" data-ts=\"1539955728\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398899-interpublic-groupplus-2_8-after-beat-driven-broad-growth\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic Group +2.8% after beat driven by broad growth</a></h4><ul>   <li>Interpublic Group (NYSE:<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a>) is <font color='green'>up 2.8%</font> premarket after beating expectations with its Q3 earnings report amid broad sales growth despite currency headwinds.</li>    <li>Revenues grew 3.4% and organic revenues even better, up 5.4%.</li>    <li>Operating income was $262M; excluding Acxiom transaction costs, it was $273M.</li>    <li>Organic net revenue growth in the U.S. was 5%, while internationally it was 6%.</li>    <li>\"These results were driven by strong top- and bottom-line performance in media, as well as growth from our three global creative networks, our marketing services agencies and our digital offerings,\" says CEO Michael Roth.</li>    <li>It reaffirmed full-year guidance for organic net revenue growth of 4%-4.5% as well as targeting 60-70 basis points of margin expansion.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398877-interpublic-group-companies-beats-0_02-beats-revenue\" target=\"_blank\">Interpublic Group of Companies beats by $0.02, beats on revenue</a> (Oct. 19 2018)</li>    <li><a href=\"http://investors.interpublic.com/news-releases/news-release-details/interpublic-announces-third-quarter-and-first-nine-months-2018\" target=\"_blank\">Press release</a></li> </ul><div class=\"tiny-share-widget\" data-id=\"3398899\" data-linked=\"Interpublic Group +2.8% after beat driven by broad growth\" data-tweet=\"$IPG - Interpublic Group +2.8% after beat driven by broad growth https://seekingalpha.com/news/3398899-interpublic-groupplus-2_8-after-beat-driven-broad-growth?source=tweet\" data-url=\"https://seekingalpha.com/news/3398899-interpublic-groupplus-2_8-after-beat-driven-broad-growth\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398894\" data-ts=\"1539955493\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DDAIF\" target=\"_blank\">DDAIF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398894-daimler-cuts-full-year-profit-outlook-for-year-on-diesel-emissions-issues\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Daimler cuts full-year profit outlook for year on diesel emissions issues</a></h4><ul>     <li>Daimler (<a href='https://seekingalpha.com/symbol/DDAIF' title='Daimler AG'>OTCPK:DDAIF</a>) plunges more than 6% in Frankfurt trading after reporting Q3 EBIT of &euro;2.48B ($2.85B), <a href=\"https://www.daimler.com/investors/reports-news/financial-news/daimler-1.html\" target=\"_blank\">down 27%</a> from &euro;3.41B in the year-ago quarter, and says it now expects full-year earnings to come in \"significantly below\" market expectations.</li><li>Daimler cites \"ongoing governmental proceedings\" and \"measures in  various regions with regard to Mercedes-Benz diesel vehicles,\" and says its vans business recorded lower unit sales due to delays in  vehicle deliveries.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3398894\" data-linked=\"Daimler cuts full-year profit outlook for year on diesel emissions issues\" data-tweet=\"$DDAIF $DMLRY - Daimler cuts full-year profit outlook for year on diesel emissions issues https://seekingalpha.com/news/3398894-daimler-cuts-full-year-profit-outlook-for-year-on-diesel-emissions-issues?source=tweet\" data-url=\"https://seekingalpha.com/news/3398894-daimler-cuts-full-year-profit-outlook-for-year-on-diesel-emissions-issues\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:24 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>7&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398892\" data-ts=\"1539955408\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/NCTY\" target=\"_blank\">NCTY</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398892-paypals-8-advance-among-premarket-gainers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PayPal&#39;s 8% advance among premarket gainers</a></h4><ul><li><a href='https://seekingalpha.com/symbol/NCTY' title='The9 Limited'>NCTY</a> <font color='green'>+406%</font>.</li><li><a href='https://seekingalpha.com/symbol/CNET' title='ChinaNet Online Holdings, Inc.'>CNET</a> <font color='green'>+53%</font>.</li><li><a href='https://seekingalpha.com/symbol/LMFA' title='LM Funding America, Inc.'>LMFA</a> <font color='green'>+36%</font>.</li><li><a href='https://seekingalpha.com/symbol/CREG' title='China Recycling Energy Corporation'>CREG</a> <font color='green'>+34%</font>.</li><li><a href='https://seekingalpha.com/symbol/AVXL' title='Anavex Life Sciences Corp.'>AVXL</a> <font color='green'>+29%</font>&nbsp;as FDA <a href=\"https://seekingalpha.com/news/3398846-fda-approves-anavex-life-sciences-ind-phase-2-trial-anavex2minus-73-shares-ahead-34-percent\" target=\"_blank\">approves</a> Anavex Life Sciences' IND for Phase 2 trial of ANAVEX2-73.</li><li><a href='https://seekingalpha.com/symbol/TAOP' title='Taoping Inc'>TAOP</a> <font color='green'>+22%</font>&nbsp;as&nbsp;five companies have <a href=\"https://seekingalpha.com/pr/17306101-taoping-alliance-welcomes-five-new-members\" target=\"_blank\">joined</a> the Taoping Alliance.</li><li><a href='https://seekingalpha.com/symbol/JMU' title='JMU Limited'>JMU</a> <font color='green'>+17%</font>.</li><li><a href='https://seekingalpha.com/symbol/CNTF' title='China TechFaith Wireless Communication Technology Limited'>CNTF</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/CCIH' title='ChinaCache International'>CCIH</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/NIHD' title='NII Holdings, Inc.'>NIHD</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/PLAG' title='Planet Green Holdings Corp'>PLAG</a> <font color='green'>+15%</font>.</li><li><a href='https://seekingalpha.com/symbol/TTGT' title='TechTarget, Inc.'>TTGT</a> <font color='green'>+10%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3398738-ttgt-plus-4-percent-fbc-plus-1_8-percent-moves-smallcap-600\" target=\"_blank\">move</a> to SmallCap 600.</li><li><a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a> <font color='green'>+10%</font>&nbsp;as V-Go insulin delivery device <a href=\"https://seekingalpha.com/news/3398862-valeritas-v-go-insulin-delivery-device-launched-italy-shares-ahead-10-percent-premarket\" target=\"_blank\">launched</a> in Italy.</li><li><a href='https://seekingalpha.com/symbol/CLDC' title='China Lending Corporation'>CLDC</a> <font color='green'>+9%</font>.</li><li><a href='https://seekingalpha.com/symbol/SKX' title='Skechers USA Inc.'>SKX</a> <font color='green'>+8%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3398652-skechers-beats-0_06-misses-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/RENN' title='Renren Inc.'>RENN</a> <font color='green'>+8%</font>.</li><li><a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a> <font color='green'>+8%</font>&nbsp;on Q3 <a href=\"https://seekingalpha.com/news/3398666-paypal-beats-0_04-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CCCL' title='China Ceramics Co., Ltd.'>CCCL</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/VLP' title='Valero Energy Partners LP'>VLP</a> <font color='green'>+7%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3398737-valero-energy-valero-energy-partners-merge\" target=\"_blank\">merger</a> with Valero Energy.</li><li><a href='https://seekingalpha.com/symbol/FBIO' title='Fortress Biotech, Inc.'>FBIO</a> <font color='green'>+12%</font>.</li><li><a href='https://seekingalpha.com/symbol/PG' title='The Procter & Gamble Company'>PG</a> <font color='green'>+6%</font>&nbsp;on Q1 <a href=\"https://seekingalpha.com/news/3398819-procter-and-gamble-beats-0_03-beats-revenue\" target=\"_blank\">result</a>.</li><li><a href='https://seekingalpha.com/symbol/CJJD' title='China Jo - Jo Drugstores, Inc.'>CJJD</a> <font color='green'>+6%</font>.</li><li><a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> <font color='green'>+5%&nbsp;</font>on <a href=\"https://seekingalpha.com/pr/17305976-clovis-oncology-presents-initial-results-ongoing-rubraca-rucaparib-triton-program-metastatic\" target=\"_blank\">announcing</a> initial data from its ongoing&nbsp;Phase 2 TRITON2&nbsp;clinical trial of Rubraca at the ESMO 2018 Congress</li></ul><div class=\"tiny-share-widget\" data-id=\"3398892\" data-linked=\"PayPal&#39;s 8% advance among premarket gainers\" data-tweet=\"$NCTY $NCTY $CNET - PayPal&#39;s 8% advance among premarket gainers https://seekingalpha.com/news/3398892-paypals-8-advance-among-premarket-gainers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398892-paypals-8-advance-among-premarket-gainers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:23 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398891\" data-ts=\"1539955242\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/XNET\" target=\"_blank\">XNET</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398891-xunleiminus-0_9-after-cuts-to-q3-revenue-guidance\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Xunlei -0.9% after cuts to Q3 revenue guidance</a></h4><ul>    <li>Xunlei Limited (NASDAQ:<a href='https://seekingalpha.com/symbol/XNET' title='Xunlei Limited'>XNET</a>) is <font color='red'>off 0.9%</font> premarket after <a href=\"https://seekingalpha.com/pr/17306013-xunlei-updates-financial-guidance-third-quarter-2018\" target=\"_blank\">trimming guidance</a> following some lower-than-expected Onething Cloud hardware sales.</li>    <li>The company expects Q3 total revenues of $43M-$46M.</li>    <li>That's down from <a href=\"https://seekingalpha.com/news/3383221-xunlei-minus-2_3-percent-gains-q2-earnings\" target=\"_blank\">earlier guidance it provided</a> for $54M-$60M.</li>    <li>Xunlei says it explored additional online and offline sales channels during Q3, an off-peak season, but as of the quarter's end those channels were still in early stages and hadn't yet generated significant sales.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398891\" data-linked=\"Xunlei -0.9% after cuts to Q3 revenue guidance\" data-tweet=\"$XNET - Xunlei -0.9% after cuts to Q3 revenue guidance https://seekingalpha.com/news/3398891-xunleiminus-0_9-after-cuts-to-q3-revenue-guidance?source=tweet\" data-url=\"https://seekingalpha.com/news/3398891-xunleiminus-0_9-after-cuts-to-q3-revenue-guidance\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:20 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398888\" data-ts=\"1539955031\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/YECO-OLD\" target=\"_blank\">YECO-OLD</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398888-plunging-bank-ozk-leading-premarket-losers\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Plunging Bank OZK leading premarket losers</a></h4><ul><li><a href='https://seekingalpha.com/symbol/YECO-OLD' title='Yulong Eco-Materials'>YECO-OLD</a> <font color='red'>-22%</font>.</li><li><a href='https://seekingalpha.com/symbol/OZK' title='Bank OZK'>OZK</a>&nbsp;<font color='red'>-22%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3398643-bank-ozk-misses-0_29-misses-revenue\" target=\"_blank\">Q3 earnings</a>.</li><li><a href='https://seekingalpha.com/symbol/BLRX' title='BioLineRx Ltd.'>BLRX</a>&nbsp;<font color='red'>-21%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17306030-biolinerx-presents-top-line-results-phase-2a-combat-keynoteminus-202-study-pancreatic-cancer\" target=\"_blank\">announcing</a> results from Phase 2a COMBAT/KEYNOTE-202 study in pancreatic cancer.</li><li><a href='https://seekingalpha.com/symbol/PTI' title='Proteostasis Therapeutics'>PTI</a> <font color='red'>-17%</font>.</li><li><a href='https://seekingalpha.com/symbol/INAP' title='Internap Network Services Corporation'>INAP</a>&nbsp;<font color='red'>-18%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3398757-internap-minus-14-percent-launching-stock-offering\" target=\"_blank\">launching</a> stock offering.</li><li><a href='https://seekingalpha.com/symbol/AKTS' title='Akoustis Technologies, Inc.'>AKTS</a>&nbsp;<font color='red'>-14%</font>&nbsp;after <a href=\"https://seekingalpha.com/news/3398756-akoustis-12-percent-announcing-stock-debt-offerings\" target=\"_blank\">announcing</a> stock, debt offerings.</li><li><a href='https://seekingalpha.com/symbol/XOG' title='Extraction Oil & Gas'>XOG</a> <font color='red'>-13%</font>&nbsp;on <a href=\"https://seekingalpha.com/pr/17305745-extraction-oil-and-gas-inc-provides-operations-guidance-update\" target=\"_blank\">providing</a> operations and guidance update.</li><li><a href='https://seekingalpha.com/symbol/SLS' title='SELLAS Life Sciences Group, Inc.'>SLS</a>&nbsp;<font color='red'>-8%</font>&nbsp;after DSMB <a href=\"https://seekingalpha.com/news/3398883-dsmb-confirms-data-mid-stage-study-neuvax-herceptin-certain-breast-cancer-patients\" target=\"_blank\">confirms</a> data from from mid-stage study of NeuVax + Herceptin.</li><li><a href='https://seekingalpha.com/symbol/YVR' title='Liquid Media Group Ltd'>YVR</a> <font color='red'>-10%</font>.</li><li><a href='https://seekingalpha.com/symbol/EBAY' title='eBay Inc.'>EBAY</a>&nbsp;<font color='red'>-6%</font>&nbsp;on <a href=\"https://seekingalpha.com/news/3398842-stifel-cuts-ebay-weak-q3-gmv-shares-minus-4-percent\" target=\"_blank\">weak</a> Q3 GMV.</li><li><a href='https://seekingalpha.com/symbol/MTNB' title='Matinas Biopharma Holdings, Inc.'>MTNB</a> <font color='red'>-7%</font>.</li><li><a href='https://seekingalpha.com/symbol/CRMD' title='CorMedix Inc.'>CRMD</a> <font color='red'>-5%</font>.</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398888\" data-linked=\"Plunging Bank OZK leading premarket losers\" data-tweet=\"$YECO-OLD $YECO-OLD $OZK - Plunging Bank OZK leading premarket losers https://seekingalpha.com/news/3398888-plunging-bank-ozk-leading-premarket-losers?source=tweet\" data-url=\"https://seekingalpha.com/news/3398888-plunging-bank-ozk-leading-premarket-losers\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:17 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>1&nbsp;<span class='comments-number'>Comment</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398887\" data-ts=\"1539954831\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398887-rbc-sees-big-upside-today-for-clovis\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">RBC sees big upside today for Clovis</a></h4><ul><li>via Notable Calls</li><li>\"We think&nbsp;these results beat expectations while approaching our most bullish view on the Street and anticipate the stock could trade between our best (+$16/sh) and base (+ $8/sh) case scenarios,\" RBC tells clients this morning.</li><li>In percentage terms, that's a&nbsp;<font color='green'>gain of between 27% and 54%</font>.</li><li><a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a> currently&nbsp;<font color='green'>higher by $1.77, or 5.9%</font>&nbsp;to $31.73.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398838-clovis-rubraca-shows-positive-action-late-stage-prostate-cancer-study\" target=\"_blank\">Clovis' Rubraca shows positive action in late-stage prostate cancer study</a> (Oct. 19)</li><li><strong>Update</strong>: Shares are down&nbsp;<font color='red'>11%</font>&nbsp;in early trade on Monday, October 22.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398887\" data-linked=\"RBC sees big upside today for Clovis\" data-tweet=\"$CLVS - RBC sees big upside today for Clovis https://seekingalpha.com/news/3398887-rbc-sees-big-upside-today-for-clovis?source=tweet\" data-url=\"https://seekingalpha.com/news/3398887-rbc-sees-big-upside-today-for-clovis\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>30&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398886\" data-ts=\"1539954796\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/PYPL\" target=\"_blank\">PYPL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398886-paypal-gains-8_1-after-after-q3-beat-btigs-venmo-based-upgrade\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">PayPal gains 8.1% after after Q3 beat, BTIG&#39;s Venmo-based upgrade</a></h4><ul><li>PayPal Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/PYPL' title='PayPal Holdings, Inc.'>PYPL</a>)&nbsp;<font color='green'>advances 8.0%</font>&nbsp;in premarket action following Q3 beat and an <a href=\"http://researchwiseny.btig.com/ResearchLibraryAnalec/DownloadResearch.aspx?E=begdbk-b\" target=\"_blank\">upgrade </a>to buy from neutral by BTIG analyst Mark Palmer, based on the progress the company's making in monetizing Venmo.</li><li>He sets a price target of $95, an upside potential of 23% based on Thursday's close of $77.48.</li><li>24% of Venmo's users engaged in a monetization event during Q3, up from 17% in Q2.</li><li>\"That figure made more meaningful the 78% increase in volume to $16.7B that Venmo reported during 3Q18, in our view,\" Palmer writes in a note.</li><li>Furthermore, the midpoint of PayPal's earnings guidance range is above consensus.</li><li>David Russell of TradeStation has a different take on PayPal's Q3 results.&nbsp; \"Earnings and revenue beat expectations slightly, but the overall payment volumes were a little light,\" he says. \"Investor sentiment toward tech, the Nasdaq, and growth have all weakened recently and PYPL&rsquo;s quarter doesn&rsquo;t suggest it will be immune to those forces.\"</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398711-paypal-gains-2-percent-hours-better-expected-q3-results\" target=\"_blank\">PayPal gains 2% after-hours on better-than-expected Q3 results</a> (Oct. 18)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398886\" data-linked=\"PayPal gains 8.1% after after Q3 beat, BTIG&#39;s Venmo-based upgrade\" data-tweet=\"$PYPL - PayPal gains 8.1% after after Q3 beat, BTIG&#39;s Venmo-based upgrade https://seekingalpha.com/news/3398886-paypal-gains-8_1-after-after-q3-beat-btigs-venmo-based-upgrade?source=tweet\" data-url=\"https://seekingalpha.com/news/3398886-paypal-gains-8_1-after-after-q3-beat-btigs-venmo-based-upgrade\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:13 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>4&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398884\" data-ts=\"1539954337\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DCPH\" target=\"_blank\">DCPH</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398884-deciphera-pharma-down-16-premarket-on-updated-early-stage-dccminus-2618-data\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Deciphera Pharma down 16% premarket on updated early-stage DCC-2618 data</a></h4><ul><li>Thinly traded Deciphera Pharmaceuticals (NASDAQ:<a href='https://seekingalpha.com/symbol/DCPH' title='Deciphera Pharmaceuticals, Inc.'>DCPH</a>) slumps&nbsp;<font color='red'>16%</font>&nbsp;premarket on modest volume in reaction to <a href=\"https://seekingalpha.com/pr/17306085-deciphera-pharmaceuticals-reports-updated-preliminary-phase-1-clinical-study-results-dccminus\" target=\"_blank\">updated data</a> from a Phase 1 study evaluating lead candidate DCC-2618 in patients with gastrointestinal stromal tumors &#40;GIST&#41;. The results are being presented at ESMO in Munich.</li><li>Investors appear to be reacting to the lower overall response rate &#40;ORR&#41; of 18% in a second-line setting, lower than 24% reported in June. The disease control rate &#40;DCR&#41;&nbsp;(responders + stable cancer) was comparable (81% vs. 80%) in the combined second- and third-line group, though.</li><li>#ESMO</li><li>Previously: <a href=\"https://seekingalpha.com/news/3361467-deciphera-pharma-33-percent-positive-dccminus-2618-data\" target=\"_blank\">Deciphera Pharma up 33% on positive DCC-2618 data</a> (June 4)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398884\" data-linked=\"Deciphera Pharma down 16% premarket on updated early-stage DCC-2618 data\" data-tweet=\"$DCPH - Deciphera Pharma down 16% premarket on updated early-stage DCC-2618 data https://seekingalpha.com/news/3398884-deciphera-pharma-down-16-premarket-on-updated-early-stage-dccminus-2618-data?source=tweet\" data-url=\"https://seekingalpha.com/news/3398884-deciphera-pharma-down-16-premarket-on-updated-early-stage-dccminus-2618-data\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  9:05 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398877\" data-ts=\"1539953527\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/IPG\" target=\"_blank\">IPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398877-interpublic-group-of-companies-beats-0_02-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Interpublic Group of Companies beats by $0.02, beats on revenue</a></h4><ul><li>Interpublic Group of Companies (NYSE:<a href='https://seekingalpha.com/symbol/IPG' title='Interpublic Group of Companies Inc.'>IPG</a>): Q3 Non-GAAP EPS of $0.48 <span style=\"color:green\">beats by $0.02</span>; GAAP EPS of $0.41 <span style=\"color:red\">misses by $0.05</span>.</li><li>Revenue of $2.29B (+3.6% Y/Y) <font color='green'>beats by $410M</font>.</li><li>Shares <font color='green'>+2.36%</font> PM.</li><li><a href='http://investors.interpublic.com/news-releases/news-release-details/interpublic-announces-third-quarter-and-first-nine-months-2018'>Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3398877\" data-linked=\"Interpublic Group of Companies beats by $0.02, beats on revenue\" data-tweet=\"$IPG - Interpublic Group of Companies beats by $0.02, beats on revenue https://seekingalpha.com/news/3398877-interpublic-group-of-companies-beats-0_02-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3398877-interpublic-group-of-companies-beats-0_02-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:52 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398876\" data-ts=\"1539953471\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CE\" target=\"_blank\">CE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398876-celaneseplus-5-after-earnings-goldman-sees-opportunistic-entry-point\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Celanese +5% after earnings; Goldman sees &#39;opportunistic entry point&#39;</a></h4><ul>     <li>Celanese (NYSE:<a href='https://seekingalpha.com/symbol/CE' title='Celanese Corporation'>CE</a>) <font color='green'>+4.9%</font> pre-market after easily beating <a href=\"https://seekingalpha.com/news/3398703-celanese-beats-0_22-misses-revenue\" target=\"_blank\">Q3 earnings</a> expectations and raising full-year EPS guidance to $10.90-$11.10, above the $10.78 analyst consensus estimate.</li>     <li>CE says its earnings performance in recent quarters underlines a sustainable upward shift in the earnings levels of both the Acetyl Chain and Engineered  Materials businesses as they each move toward becoming enterprises with $1B in adjusted EBITDA by 2020.</li>     <li>CE trades at a discount compared to the company&rsquo;s earnings  outlook and \"mis-match [which] presents an opportunistic entry point,\" says Goldman Sachs analyst Brian Maguire, who rates the stock as a Conviction List Buy with a $132 price target.</li>     <li>Maguire says CE&rsquo;s shares came under pressure due to PPG&rsquo;s Oct. 8 warning, but CE&rsquo;s Q3 results show the attraction of its differentiated Engineered Materials platform accentuated by 8% organic growth to the auto OEM market, far outpacing declining global build rates in Q3.</li><li>Source:&nbsp;Bloomberg First Word</li> </ul><div class=\"tiny-share-widget\" data-id=\"3398876\" data-linked=\"Celanese +5% after earnings; Goldman sees &#39;opportunistic entry point&#39;\" data-tweet=\"$CE - Celanese +5% after earnings; Goldman sees &#39;opportunistic entry point&#39; https://seekingalpha.com/news/3398876-celaneseplus-5-after-earnings-goldman-sees-opportunistic-entry-point?source=tweet\" data-url=\"https://seekingalpha.com/news/3398876-celaneseplus-5-after-earnings-goldman-sees-opportunistic-entry-point\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:51 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398871\" data-ts=\"1539953116\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/DIS\" target=\"_blank\">DIS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398871-barclays-upgrades-disney-on-streaming-pivot\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Barclays upgrades Disney on streaming pivot</a></h4><ul><li>        Barclays <a href=\"https://www.cnbc.com/2018/10/19/barclays-upgrades-disney-on-pivot-to-streaming.html\" target=\"_blank\">upgrades</a> Disney (NYSE:<a href='https://seekingalpha.com/symbol/DIS' title='The Walt Disney Company'>DIS</a>) from Equal Weight to Overweight and raises its target by $25 to $130.</li><li>               The firm cites Disney&rsquo;s recent pivot to streaming. &nbsp;&nbsp;</li><li>               Upcoming catalyst: Barclays says the investor day expected early next year could be &ldquo;a catalyst to frame the scale of the opportunity and help the company build a credible terminal value &lsquo;story&rsquo; around the stock.&rdquo; &nbsp;&nbsp;</li><li>               Disney shares are&nbsp;<font color='green'>up 1.4%</font>&nbsp;premarket to $117.82.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</li></ul><div class=\"tiny-share-widget\" data-id=\"3398871\" data-linked=\"Barclays upgrades Disney on streaming pivot\" data-tweet=\"$DIS - Barclays upgrades Disney on streaming pivot https://seekingalpha.com/news/3398871-barclays-upgrades-disney-on-streaming-pivot?source=tweet\" data-url=\"https://seekingalpha.com/news/3398871-barclays-upgrades-disney-on-streaming-pivot\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:45 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>18&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398867\" data-ts=\"1539952565\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STI\" target=\"_blank\">STI</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398867-suntrust-gains-2_5-premarket-q3-beats-consensus\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">SunTrust gains 2.5% premarket as Q3 beats consensus</a></h4><ul><li>SunTrust Banks (NYSE:<a href='https://seekingalpha.com/symbol/STI' title='SunTrust Banks, Inc.'>STI</a>) posts <a href=\"https://seekingalpha.com/pr/17305974-suntrust-reports-third-quarter-2018-results\" target=\"_blank\">Q3 EPS of $1.56</a>, including 14-cent tax benefit from the impact of tax reform and the consolidation of SunTrust Mortgage into SunTrust Bank, beating consensus estimate by 17 cents.</li><li>SunTrust climbs 2.5% in premarket trading</li><li>\"We have revenue momentum going into the fourth quarter of the year, and 2018 is on track to be the seventh consecutive year of growth in earnings per share, improved efficiency, and higher capital returns,\" says Chairman and CEO William H. Rogers, Jr.</li><li>Q3 total revenue of $2.29B fell from $2.32B in Q2 and was up slightly from $2.28B in the year-ago quarter.</li><li>Q3 Net interest income of $1.51B rose from $1.49B in Q2 and $1.43B a year ago; net interest margin-FTE was 3.27% vs. 3.28% in Q2 and 3.15% a year ago.</li><li>Q3 provision for credit losses of $61M rises from $32M in Q2, but almost half of the $120M provision in Q3 2017.</li><li>Q3 average performing loans held for investment increased 1% vs. Q2, driven by growth in C&amp;I, CRE, residential mortgages, and consumer direct loans.</li><li>Q3 return on average common shareholders' equity 13.01% vs. 9.03% a year ago.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398789-suntrust-banks-beats-0_17-misses-revenue\" target=\"_blank\">SunTrust Banks beats by $0.17, misses on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398867\" data-linked=\"SunTrust gains 2.5% premarket as Q3 beats consensus\" data-tweet=\"$STI - SunTrust gains 2.5% premarket as Q3 beats consensus https://seekingalpha.com/news/3398867-suntrust-gains-2_5-premarket-q3-beats-consensus?source=tweet\" data-url=\"https://seekingalpha.com/news/3398867-suntrust-gains-2_5-premarket-q3-beats-consensus\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:36 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398866\" data-ts=\"1539952522\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VRTX\" target=\"_blank\">VRTX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398866-ema-advisory-group-backs-new-indications-for-three-meds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">EMA advisory group backs new indications for three meds</a></h4><ul><li>The European Medicines Agency's advisory group CHMP has adopted <a href=\"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018\" target=\"_blank\">positive opinions</a> backing expanded uses for the following drugs:</li><li>Vertex Pharmaceuticals' (NASDAQ:<a href='https://seekingalpha.com/symbol/VRTX' title='Vertex Pharmaceuticals Incorporated'>VRTX</a>) Kalydeco (ivacaftor) for use in children as young as 12 months old.</li><li>Merck's (NYSE:<a href='https://seekingalpha.com/symbol/MRK' title='Merck & Co Inc.'>MRK</a>) Keytruda (pembrolizumab) as&nbsp;adjuvant treatment of melanoma in adults with lymph node involvement who have undergone complete resection.</li><li>Novo Nordisk's (NYSE:<a href='https://seekingalpha.com/symbol/NVO' title='Novo Nordisk A/S'>NVO</a>) NovoSeven (eptacog alfa) in patients with Glanzmann&rsquo;s thrombasthenia, past or present resistance to platelet transfusions or where platelets are not readily available.</li><li>Final decisions from the European Commision usually take ~60 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398866\" data-linked=\"EMA advisory group backs new indications for three meds\" data-tweet=\"$VRTX $VRTX $MRK - EMA advisory group backs new indications for three meds https://seekingalpha.com/news/3398866-ema-advisory-group-backs-new-indications-for-three-meds?source=tweet\" data-url=\"https://seekingalpha.com/news/3398866-ema-advisory-group-backs-new-indications-for-three-meds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:35 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398864\" data-ts=\"1539952308\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/OCUL\" target=\"_blank\">OCUL</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398864-ocular-therapeutix-receives-fda-warning-letter-related-to-resure-sealant\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Ocular Therapeutix receives FDA warning letter related to ReSure Sealant</a></h4><ul> <li>Ocular Therapeutix (NASDAQ:<a href='https://seekingalpha.com/symbol/OCUL' title='Ocular Therapeutix'>OCUL</a>) has <a href=\"https://seekingalpha.com/pr/17306069-ocular-therapeutix-receives-fda-warning-letter-related-resure-sealant\" target=\"_blank\">received</a> a warning letter from the FDA related to Ocular&rsquo;s compliance with data collection and       information reporting obligations in a post-approval Device Exposure       Registry study required as a condition for approval of the premarket       approval application for ReSure Sealant.</li><li>The Company is required       to provide periodic reports to the FDA on the progress of this       post-approval study until it is completed.</li><li>OCUL down&nbsp;<font color='red'>6%</font>&nbsp;premarket.</li>     </ul><div class=\"tiny-share-widget\" data-id=\"3398864\" data-linked=\"Ocular Therapeutix receives FDA warning letter related to ReSure Sealant\" data-tweet=\"$OCUL - Ocular Therapeutix receives FDA warning letter related to ReSure Sealant https://seekingalpha.com/news/3398864-ocular-therapeutix-receives-fda-warning-letter-related-to-resure-sealant?source=tweet\" data-url=\"https://seekingalpha.com/news/3398864-ocular-therapeutix-receives-fda-warning-letter-related-to-resure-sealant\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:31 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398863\" data-ts=\"1539952102\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VFC\" target=\"_blank\">VFC</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398863-vf-corp-moves-up-after-q2-beat-upsized-guidance-dividend-hike\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">VF Corp. moves up after Q2 beat, upsized guidance, dividend hike</a></h4><ul>     <li>VF&nbsp;Corp. (NYSE:<a href='https://seekingalpha.com/symbol/VFC' title='V.F. Corporation'>VFC</a>)&nbsp;<font color='green'>+1.7%</font> pre-market after <a href=\"https://seekingalpha.com/news/3398812-v-f-corp-beats-0_10-beats-revenue\" target=\"_blank\">FQ2 earnings</a> and revenue both top analyst expectations while also guiding 2019 earnings above consensus and <a href=\"https://seekingalpha.com/news/3398833-v-f-corp-declares-0_51-dividend\" target=\"_blank\">raising its dividend</a> by 11%.</li>     <li>Revenue rose 15% to $3.91B from $3.39B in the year-ago quarter, including a 26% jump for the Vans brand and a 5% increase for North Face; international revenue rose 13%.</li>     <li>FQ2 gross margin declined 10 bps to 50.1%, as the impact of acquisitions was partially offset by a mix-shift toward higher margin businesses and continued focus on fundamentals; excluding acquisitions, adjusted gross margin rose 70 bps to 50.9%.</li><li>VF raises its FY 2019 guidance, now seeing EPS of $3.65 vs. its previous outlook of $3.52-$3.57 and above the $3.63 analyst consensus estimate, with revenue of $13.7B vs. its prior view of $13.6B-$13.7B and in-line with $13.7B consensus.</li>      </ul><div class=\"tiny-share-widget\" data-id=\"3398863\" data-linked=\"VF Corp. moves up after Q2 beat, upsized guidance, dividend hike\" data-tweet=\"$VFC - VF Corp. moves up after Q2 beat, upsized guidance, dividend hike https://seekingalpha.com/news/3398863-vf-corp-moves-up-after-q2-beat-upsized-guidance-dividend-hike?source=tweet\" data-url=\"https://seekingalpha.com/news/3398863-vf-corp-moves-up-after-q2-beat-upsized-guidance-dividend-hike\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>41&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398862\" data-ts=\"1539952090\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/VLRX\" target=\"_blank\">VLRX</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398862-valeritas-v-go-insulin-delivery-device-launched-in-italy-shares-ahead-10-premarket\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Valeritas&#39; V-Go insulin delivery device launched in Italy; shares ahead 10% premarket</a></h4><ul> <li>Valeritas Holdings (NASDAQ:<a href='https://seekingalpha.com/symbol/VLRX' title='Valeritas Holdings, Inc.'>VLRX</a>) <a href=\"https://seekingalpha.com/pr/17306019-valeritas-announces-v-go-insulin-delivery-device-launched-italy\" target=\"_blank\">announces</a> that V-Go has launched and is now available in Italy through its distribution agreement with Movi SpA.</li>     <li>Italy is the first European country to officially introduce this device that will help people with Type II diabetes.</li>        <li>Through the distribution agreement, Valeritas will retain responsibility for product development, regulatory approval, quality management, and manufacturing while Movi will be responsible for sales, marketing, customer support, and distribution activities in Italy.</li><li>VLRX up&nbsp;<font color='green'>10%</font>&nbsp;premarket.</li>    </ul><div class=\"tiny-share-widget\" data-id=\"3398862\" data-linked=\"Valeritas&#39; V-Go insulin delivery device launched in Italy; shares ahead 10% premarket\" data-tweet=\"$VLRX - Valeritas&#39; V-Go insulin delivery device launched in Italy; shares ahead 10% premarket https://seekingalpha.com/news/3398862-valeritas-v-go-insulin-delivery-device-launched-in-italy-shares-ahead-10-premarket?source=tweet\" data-url=\"https://seekingalpha.com/news/3398862-valeritas-v-go-insulin-delivery-device-launched-in-italy-shares-ahead-10-premarket\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:28 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398860\" data-ts=\"1539951996\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/SHPG\" target=\"_blank\">SHPG</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398860-european-advisory-group-backs-six-new-meds\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">European advisory group backs six new meds</a></h4><ul><li>The European Medicines Agency's advisory group CHMP <a href=\"https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-15-18-october-2018\" target=\"_blank\">recommends </a>the following medicines for approval:</li><li>Shire plc's (NASDAQ:<a href='https://seekingalpha.com/symbol/SHPG' title='Shire PLC'>SHPG</a>) Takhyzyro (lanadelumab) for angioedema attacks.</li><li>Lupin Europe GmbH's Namuscla (mexiletine hydrochloride) for myotonia in adults with non-dystrophic myotonic disorders.</li><li>Sanofi Pasteur's (NASDAQ:<a href='https://seekingalpha.com/symbol/SNY' title='Sanofi'>SNY</a>) Dengvaxia [dengue tetravalent vaccine (live, attenuated)] for the prevention of dengue disease.</li><li>Seqirus Netherlands B.V.'s Flucelvax Tetra (influenza vaccine surface antigen inactivated prepared cell cultures) for the prevention of flu in patients at least nine years old.</li><li>AstraZeneca's (NYSE:<a href='https://seekingalpha.com/symbol/AZN' title='AstraZeneca Group plc'>AZN</a>) Bevespi Aerosphere (glycopyrronium/formoterol fumarate dihydrate) for the maintenance treatment of COPD.</li><li>Mylan's (NASDAQ:<a href='https://seekingalpha.com/symbol/MYL' title='Mylan Inc'>MYL</a>) Ogivri (trastuzumab), a biosimilar to Roche's (<a href='https://seekingalpha.com/symbol/RHHBY' title='Roche Holding Ltd ADR'>OTCQX:RHHBY</a>) Herceptin.</li><li>Final decisions from the European Commission usually take ~60 days.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398860\" data-linked=\"European advisory group backs six new meds\" data-tweet=\"$SHPG $SHPG $SNY - European advisory group backs six new meds https://seekingalpha.com/news/3398860-european-advisory-group-backs-six-new-meds?source=tweet\" data-url=\"https://seekingalpha.com/news/3398860-european-advisory-group-backs-six-new-meds\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:26 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>2&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398858\" data-ts=\"1539951298\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/ADBE\" target=\"_blank\">ADBE</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398858-wedbush-out-positive-on-adobe-starts-neutral\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Wedbush out positive on Adobe but starts Neutral</a></h4><ul><li>        Wedbush initiates Adobe (NASDAQ:<a href='https://seekingalpha.com/symbol/ADBE' title='Adobe Systems Incorporated'>ADBE</a>) with a Neutral rating and a $270 price target, an 8% upside to yesterday&rsquo;s close.</li><li>               The firm says Adobe management has &ldquo;engineered a Picasso-like model transition from its original license roots to a subscription based business&rdquo; that was &ldquo;flawless&rdquo; with &ldquo;minimal speed bumps.&rdquo; &nbsp;&nbsp;</li><li>               Wedbush is neutral on the currently balanced risk/reward on shares but expects ARPU expansion, more price increases, and positive growth catalysts in the next few years.&nbsp;</li><li>               Upcoming catalysts: This year&rsquo;s Marketo and Magneto acquisitions will start showing more numbers. The next earnings report is expected in mid-December.&nbsp;</li><li>               Source: Research note.&nbsp;</li><li>                  Adobe shares are&nbsp;<font color='green'>up 1%</font>&nbsp;premarket to $252.92.&nbsp;&nbsp;&nbsp; </li></ul><div class=\"tiny-share-widget\" data-id=\"3398858\" data-linked=\"Wedbush out positive on Adobe but starts Neutral\" data-tweet=\"$ADBE - Wedbush out positive on Adobe but starts Neutral https://seekingalpha.com/news/3398858-wedbush-out-positive-on-adobe-starts-neutral?source=tweet\" data-url=\"https://seekingalpha.com/news/3398858-wedbush-out-positive-on-adobe-starts-neutral\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:14 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>6&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398857\" data-ts=\"1539951093\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/STT\" target=\"_blank\">STT</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398857-on-state-street-q3-revenue-slips-on-client-transitions-challenging-conditions\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">More on State Street Q3: Revenue slips on client transitions, challenging conditions</a></h4><ul><li>State Street (NYSE:<a href='https://seekingalpha.com/symbol/STT' title='State Street Corporation'>STT</a>)<a href=\"https://seekingalpha.com/pr/17306000-state-street-reports-third-quarter-2018-eps-1_87-13-percent-roe-14-percent-1-percentage-point\" target=\"_blank\"> Q3 net income</a> of $709M, or $1.87, rises from $698M in Q2, or $1.88, in Q2 and $629M, or $1.66, a year ago; Q3 EPS falls short of $1.89 consensus estimate.</li><li>STT<font color='red'> -2.1%</font>&nbsp;in premarket trading.</li><li>Q3 total revenue of $2.95B falls 3.7% from Q2, rises 2.9% from a year ago; misses consensus of $3.02B; servicing fees fell 1.3% Y/Y mostly due to previously announced client transitions and challenging industry conditions.</li><li>Sees Beacon program 2018 net savings about $200M, exceeding initial guidance of $150M; realized $65M of savings in Q3.</li><li>Q3 net interest income of $672M rose 2.0% from Q2 and 11% Y/Y.</li><li>Q3 net interest margin of 1.48% vs. 1.46% in Q2 and 1.35% a year ago.</li><li>Q3 assets under custody and administration $34.0T, up 0.2% from $33.9T in Q2 and up 5.9% from $32.1T a year ago.</li><li>Q3 assets under management of $2.81T rose 3.2% from Q2's $2.72T and 5.1% from $2.67T in Q3 2017.</li></ul><ol><li>Long-term institutional net flows were $29B inflows in equity, $11B outflows in fixed income; $1B outflows in multi-asset class solutions, and $2B outflows in alternative investments.</li><li>Market appreciation was $85B in equity, negative $4B in fixed income; $3B in cash, $2B in multi-asset class solutions; and nil in alternative investments.</li></ol><ul><li>Q3 return on average common equity 14.0% vs. 14.7% in Q2 and 13.0% in Q3 2017.</li><li>Previously: <a href=\"https://seekingalpha.com/news/3398821-state-street-misses-0_02-misses-revenue\" target=\"_blank\">State Street misses by $0.02, misses on revenue</a> (Oct. 19)</li></ul><div class=\"tiny-share-widget\" data-id=\"3398857\" data-linked=\"More on State Street Q3: Revenue slips on client transitions, challenging conditions\" data-tweet=\"$STT - More on State Street Q3: Revenue slips on client transitions, challenging conditions https://seekingalpha.com/news/3398857-on-state-street-q3-revenue-slips-on-client-transitions-challenging-conditions?source=tweet\" data-url=\"https://seekingalpha.com/news/3398857-on-state-street-q3-revenue-slips-on-client-transitions-challenging-conditions\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:11 AM </div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398854\" data-ts=\"1539950677\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLF\" target=\"_blank\">CLF</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398854-cleveland-cliffs-misses-0_03-beats-on-revenue\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Cleveland-Cliffs misses by $0.03, beats on revenue</a></h4><ul><li>Cleveland-Cliffs (NYSE:<a href='https://seekingalpha.com/symbol/CLF' title='Cleveland-Cliffs, Inc.'>CLF</a>): Q3 GAAP EPS from continuing operations of $0.64<font color='red'> misses by $0.03</font>; Diluted EPS of $1.41.</li><li>Revenue of $742M (+24.3% Y/Y) <font color='green'>beats by $20.4M</font>.</li><li>Shares <font color='green'>+4.9%</font> PM.</li><li><a href=\"https://seekingalpha.com/pr/17306091-cleveland-cliffs-inc-reports-third-quarter-2018-results-initiates-quarterly-cash-dividend\" target=\"_blank\">Press Release</a></li></ul><div class=\"tiny-share-widget\" data-id=\"3398854\" data-linked=\"Cleveland-Cliffs misses by $0.03, beats on revenue\" data-tweet=\"$CLF - Cleveland-Cliffs misses by $0.03, beats on revenue https://seekingalpha.com/news/3398854-cleveland-cliffs-misses-0_03-beats-on-revenue?source=tweet\" data-url=\"https://seekingalpha.com/news/3398854-cleveland-cliffs-misses-0_03-beats-on-revenue\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:04 AM <span class='mc_gray_separator'>|</span> <span class='comments-n'><span class='comments-container '>69&nbsp;<span class='comments-number'>Comments</span></span></span></div></div></li><li class=\"n-box-item sa-box-item\" data-id=\"3398852\" data-ts=\"1539950590\"><div class=\"media media-overflow-fix\"><div class=\"media-left\"><a class=\"box-ticker\" href=\"/symbol/CLVS\" target=\"_blank\">CLVS</a></div><div class=\"media-body\"><h4 class=\"media-heading\"><a href=\"/news/3398852-premarket-analyst-action-healthcare\" sasource=\"on_the_move_news_fidelity\" target=\"_blank\">Premarket analyst action - healthcare</a></h4><ul><li>Clovis Oncology (NASDAQ:<a href='https://seekingalpha.com/symbol/CLVS' title='Clovis Oncology'>CLVS</a>) resumed with Neutral rating and $33 (10% upside) price target at Piper Jaffray. Shares up&nbsp;<font color='green'>11%</font>&nbsp;premarket on Rubrace data in mCRPC.</li><li>Immunomedics (NASDAQ:<a href='https://seekingalpha.com/symbol/IMMU' title='Immunomedics, Inc.'>IMMU</a>) initiated with Overweight rating and $33 (45% upside) price target at Piper.</li><li>Quest Diagnostics (NYSE:<a href='https://seekingalpha.com/symbol/DGX' title='Quest Diagnostics Incorporated'>DGX</a>) resumed with Buy rating and $116 (14% upside) price target at BofA/Merrill Lynch.</li><li>Halozyme (NASDAQ:<a href='https://seekingalpha.com/symbol/HALO' title='Halozyme Therapeutics, Inc.'>HALO</a>) resumed with Neutral rating and $17 (flat) price target at Piper.</li><li>LabCorp (NYSE:<a href='https://seekingalpha.com/symbol/LH' title='Laboratory Corporation of America Holdings'>LH</a>) resumed with Buy rating and $197 (15% upside) price target at BofA/Merrill Lynch.</li><li>Patterson Companies (NASDAQ:<a href='https://seekingalpha.com/symbol/PDCO' title='Patterson Companies Inc.'>PDCO</a>) resumed with Sell rating at Goldman Sachs.</li><li>Henry Schein (NASDAQ:<a href='https://seekingalpha.com/symbol/HSIC' title='Henry Schein, Inc.'>HSIC</a>) resumed with Neutral rating at Goldman.</li><li>Pacific Biosciences of California (NASDAQ:<a href='https://seekingalpha.com/symbol/PACB' title='Pacific Biosciences of California'>PACB</a>) initiated with Outperform rating and $6.50 (44% upside) price target at Cowen and Company.</li><li>DexCom (NASDAQ:<a href='https://seekingalpha.com/symbol/DXCM' title='DexCom, Inc.'>DXCM</a>) upgraded to Neutral with a $125 (6% downside risk) price target at Goldman Sachs.</li><li>Intuitive Surgical (NASDAQ:<a href='https://seekingalpha.com/symbol/ISRG' title='Intuitive Surgical, Inc.'>ISRG</a>) upgraded to Buy with a $610 (17% upside) price target at Canaccord Genuity following Q3 results. Shares up&nbsp;<font color='green'>2%</font>&nbsp;premarket.</li><li>DENTSPLY SIRONA (NASDAQ:<a href='https://seekingalpha.com/symbol/XRAY' title='DENTSPLY SIRONA, Inc'>XRAY</a>) upgraded to Outperform with a $44 (23% upside) price target at IFS Securities. Upgraded to Buy at Goldman. Shares up&nbsp;<font color='green'>3%</font>&nbsp;premarket.</li><li>Syneos Health (NASDAQ:<a href='https://seekingalpha.com/symbol/SYNH' title='Syneos Health, Inc.'>SYNH</a>) upgraded to Outperform at William Blair.</li><li>Biogen (NASDAQ:<a href='https://seekingalpha.com/symbol/BIIB' title='Biogen Inc.'>BIIB</a>) downgraded to Market Perform at Bernstein. Shares down&nbsp;<font color='red'>1%&nbsp;</font>premarket.</li><li>Rockwell Medical (NASDAQ:<a href='https://seekingalpha.com/symbol/RMTI' title='Rockwell Medical, Inc.'>RMTI</a>) downgraded to Outperform with an $11 (156% upside) price target at IFS Securities.</li><li>Nevro (NYSE:<a href='https://seekingalpha.com/symbol/NVRO' title='Nevro'>NVRO</a>) downgraded to Sell at Goldman. Shares down&nbsp;<font color='red'>5%</font>&nbsp;premarket.</li></ul><div class=\"tiny-share-widget\" data-id=\"3398852\" data-linked=\"Premarket analyst action - healthcare\" data-tweet=\"$CLVS $CLVS $IMMU - Premarket analyst action - healthcare https://seekingalpha.com/news/3398852-premarket-analyst-action-healthcare?source=tweet\" data-url=\"https://seekingalpha.com/news/3398852-premarket-analyst-action-healthcare\"><div class=\"icon share-btn c-email\" title=\"Email a friend\">&nbsp;</div><div class=\"icon share-btn c-twitter\" title=\"Share on Twitter\">&nbsp;</div><div class=\"icon share-btn c-facebook\" title=\"Share on Facebook\">&nbsp;</div><div class=\"icon share-btn c-linkedin\" title=\"Share on Linkedin\">&nbsp;</div></div><span class=\"mc_gray_separator\">|</span>  8:03 AM </div></div></li>","count":75,"message":null,"success":true,"today":{"start":1577077200,"end":1577163599,"str":"Monday, December 23, 2019"},"yesterday":{"start":1576990800,"end":1577077199}}